WO2015131856A1 - 一类杂环化合物、其制备方法和用途 - Google Patents
一类杂环化合物、其制备方法和用途 Download PDFInfo
- Publication number
- WO2015131856A1 WO2015131856A1 PCT/CN2015/073854 CN2015073854W WO2015131856A1 WO 2015131856 A1 WO2015131856 A1 WO 2015131856A1 CN 2015073854 W CN2015073854 W CN 2015073854W WO 2015131856 A1 WO2015131856 A1 WO 2015131856A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- piperazin
- ethyl
- alkyl
- alkoxy
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 172
- 150000002391 heterocyclic compounds Chemical class 0.000 title claims abstract description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- 150000003839 salts Chemical class 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims abstract description 13
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- -1 hydroxy, decyl Chemical group 0.000 claims description 236
- 238000006243 chemical reaction Methods 0.000 claims description 97
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 88
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 58
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 55
- 125000004432 carbon atom Chemical group C* 0.000 claims description 36
- 125000002252 acyl group Chemical group 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 32
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 125000001425 triazolyl group Chemical group 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- 125000003277 amino group Chemical group 0.000 claims description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 19
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 16
- 239000000460 chlorine Substances 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- 125000000335 thiazolyl group Chemical group 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 15
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 14
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 14
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 14
- 125000001544 thienyl group Chemical group 0.000 claims description 14
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000002541 furyl group Chemical group 0.000 claims description 13
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 12
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000003172 aldehyde group Chemical group 0.000 claims description 11
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 11
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims description 11
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 11
- 125000002971 oxazolyl group Chemical group 0.000 claims description 11
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 11
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 11
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 11
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 11
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 11
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 10
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 208000024714 major depressive disease Diseases 0.000 claims description 10
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 10
- 125000004193 piperazinyl group Chemical group 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 9
- 239000011737 fluorine Substances 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 9
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 7
- FPVHORFNDSKMPV-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2O)C FPVHORFNDSKMPV-UHFFFAOYSA-N 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 150000001299 aldehydes Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 208000019022 Mood disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 238000007112 amidation reaction Methods 0.000 claims description 5
- 125000005997 bromomethyl group Chemical group 0.000 claims description 5
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 4
- 208000017194 Affective disease Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000027534 Emotional disease Diseases 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims description 3
- QZEQIKIXOMIHER-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidine-4,9-dione Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2=O)C QZEQIKIXOMIHER-UHFFFAOYSA-N 0.000 claims description 3
- ZMXMHHBSWXBDPL-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-9-chloro-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2Cl)C ZMXMHHBSWXBDPL-UHFFFAOYSA-N 0.000 claims description 3
- VKNIGNGTZIYLFI-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-9-fluoro-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2F)C VKNIGNGTZIYLFI-UHFFFAOYSA-N 0.000 claims description 3
- YYHRMWYQOMFFHW-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound S1C2=C(C=C1)C(=CC=C2)C1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2O)C YYHRMWYQOMFFHW-UHFFFAOYSA-N 0.000 claims description 3
- NFONCWBZHQCTIA-UHFFFAOYSA-N 3-[2-[4-(2,3-dihydro-1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound S1C2=C(CC1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2O)C NFONCWBZHQCTIA-UHFFFAOYSA-N 0.000 claims description 3
- FFIQSCOADWZDLK-UHFFFAOYSA-N 7-[5-[4-(1-benzothiophen-4-yl)piperazin-1-yl]pentyl]-1H-quinolin-2-one Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCCC1=CC=C2C=CC(NC2=C1)=O FFIQSCOADWZDLK-UHFFFAOYSA-N 0.000 claims description 3
- KENWLBJSTKCVPJ-UHFFFAOYSA-N 7-[5-[4-(1-benzothiophen-4-yl)piperazin-1-yl]pentyl]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C2NC(=O)CCC2=CC=C1CCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 KENWLBJSTKCVPJ-UHFFFAOYSA-N 0.000 claims description 3
- BVMHGNCIMARWAI-UHFFFAOYSA-N 9-hydroxy-2-methyl-3-[2-(4-thieno[2,3-d]pyrimidin-4-ylpiperazin-1-yl)ethyl]-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound OC1CCCN2C1=NC(=C(C2=O)CCN1CCN(CC1)C=1C2=C(N=CN=1)SC=C2)C BVMHGNCIMARWAI-UHFFFAOYSA-N 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- HSKMUBMPYUHCJC-UHFFFAOYSA-N ClC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCCCCC1=CC=C2C=CC(NC2=C1)=O Chemical compound ClC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCCCCC1=CC=C2C=CC(NC2=C1)=O HSKMUBMPYUHCJC-UHFFFAOYSA-N 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- PUNRMOUVAWBZQV-UHFFFAOYSA-N N1=CN=C(C2=C1SC=C2)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O Chemical compound N1=CN=C(C2=C1SC=C2)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O PUNRMOUVAWBZQV-UHFFFAOYSA-N 0.000 claims description 3
- ARKONYMAARJBGT-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)C1=CCN(CC1)CCCCCC1=CC=C2C=CC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)C1=CCN(CC1)CCCCCC1=CC=C2C=CC(NC2=C1)=O ARKONYMAARJBGT-UHFFFAOYSA-N 0.000 claims description 3
- ZZXCUYYHIRLXPO-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(C=C2C=CC(NC2=C1)=O)Cl Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(C=C2C=CC(NC2=C1)=O)Cl ZZXCUYYHIRLXPO-UHFFFAOYSA-N 0.000 claims description 3
- HIEBSROLKYHUCT-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(C=C2CCC(NC2=C1)=O)Cl Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(C=C2CCC(NC2=C1)=O)Cl HIEBSROLKYHUCT-UHFFFAOYSA-N 0.000 claims description 3
- WZGDKWUZLJPAQO-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(NC(N2)=O)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(NC(N2)=O)C=C1 WZGDKWUZLJPAQO-UHFFFAOYSA-N 0.000 claims description 3
- KWRGINFICPLLIP-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O KWRGINFICPLLIP-UHFFFAOYSA-N 0.000 claims description 3
- SZYUTISKQDLLGP-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=S Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=S SZYUTISKQDLLGP-UHFFFAOYSA-N 0.000 claims description 3
- GPDSIVWKHXYNJS-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2CCC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2CCC(NC2=C1)=O GPDSIVWKHXYNJS-UHFFFAOYSA-N 0.000 claims description 3
- GUSVRDBRCZEWHY-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CNC2=CC=CC=C12 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CNC2=CC=CC=C12 GUSVRDBRCZEWHY-UHFFFAOYSA-N 0.000 claims description 3
- MZWXQBFYLBCQDO-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=NC2=CC=CC=C2C(N1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=NC2=CC=CC=C2C(N1)=O MZWXQBFYLBCQDO-UHFFFAOYSA-N 0.000 claims description 3
- WPEVHEZOLHWIEX-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCC1=CC=C2C=CC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCC1=CC=C2C=CC(NC2=C1)=O WPEVHEZOLHWIEX-UHFFFAOYSA-N 0.000 claims description 3
- OQSPWUFSIHNMPK-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CC=C2C=CC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CC=C2C=CC(NC2=C1)=O OQSPWUFSIHNMPK-UHFFFAOYSA-N 0.000 claims description 3
- DVWFBFACSVVQQZ-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CC=C2CCC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CC=C2CCC(NC2=C1)=O DVWFBFACSVVQQZ-UHFFFAOYSA-N 0.000 claims description 3
- MKFLLIOTPQMWSL-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCCC=1C=C2C(NC(=NC2=CC=1)C)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCCC=1C=C2C(NC(=NC2=CC=1)C)=O MKFLLIOTPQMWSL-UHFFFAOYSA-N 0.000 claims description 3
- KXADBRPCRIFTTK-UHFFFAOYSA-N S1C2=C(CC1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O Chemical compound S1C2=C(CC1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O KXADBRPCRIFTTK-UHFFFAOYSA-N 0.000 claims description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 3
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 claims description 3
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 3
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 claims description 3
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 claims description 3
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims description 3
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 238000006268 reductive amination reaction Methods 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims description 3
- UGARFWZIGMXQJJ-DUXKGJEZSA-N (3aR,4R,6aS)-4-[5-[4-(1-benzothiophen-4-yl)piperazin-1-yl]pentyl]-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC[C@H]1SC[C@H]2NC(N[C@H]21)=O UGARFWZIGMXQJJ-DUXKGJEZSA-N 0.000 claims description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- QPDFGKXMWWLYOX-UHFFFAOYSA-N 1-[2-[4-(2-cyano-7-fluoro-1-benzothiophen-4-yl)-2-methylpiperazin-1-yl]ethyl]-3,4-dihydro-1h-isochromene-6-carboxamide Chemical compound C1CN(CCC2C3=CC=C(C=C3CCO2)C(N)=O)C(C)CN1C1=CC=C(F)C2=C1C=C(C#N)S2 QPDFGKXMWWLYOX-UHFFFAOYSA-N 0.000 claims description 2
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims description 2
- GJTQRHFCZWUPOH-UHFFFAOYSA-N 2-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-4H-1,4-benzoxazin-3-one Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1C(NC2=C(O1)C=CC=C2)=O GJTQRHFCZWUPOH-UHFFFAOYSA-N 0.000 claims description 2
- OHSHVZPWRGUHCW-UHFFFAOYSA-N 2-methyl-3-[2-(4-thieno[2,3-d]pyrimidin-4-ylpiperazin-1-yl)ethyl]-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound CC=1N=C2N(C(C=1CCN1CCN(CC1)C=1C3=C(N=CN=1)SC=C3)=O)CCCC2 OHSHVZPWRGUHCW-UHFFFAOYSA-N 0.000 claims description 2
- UPSLECAHIMQGDX-UHFFFAOYSA-N 2h-pyran-6-carboxamide Chemical compound NC(=O)C1=CC=CCO1 UPSLECAHIMQGDX-UHFFFAOYSA-N 0.000 claims description 2
- CFGLHQSIGAVKRU-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-9,9-difluoro-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4-one Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2(F)F)C CFGLHQSIGAVKRU-UHFFFAOYSA-N 0.000 claims description 2
- FIIKFPYCOKYZNU-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-9-hydroxy-2,9-dimethyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4-one Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2(C)O)C FIIKFPYCOKYZNU-UHFFFAOYSA-N 0.000 claims description 2
- WKMZFHJPWGOTTD-UHFFFAOYSA-N 3-[2-[4-(6-fluoro-1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC=1C=C(C2=C(SC=C2)C=1)N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2)C WKMZFHJPWGOTTD-UHFFFAOYSA-N 0.000 claims description 2
- QAVPFQUBNUOULL-UHFFFAOYSA-N 3-[3-[4-(1-benzothiophen-4-yl)piperazin-1-yl]propyl]-1-(4-methylphenyl)sulfonylindole-5-carbonitrile Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCC1=CN(C2=CC=C(C=C12)C#N)S(=O)(=O)C1=CC=C(C)C=C1 QAVPFQUBNUOULL-UHFFFAOYSA-N 0.000 claims description 2
- JKXHFLZXUGHMGM-UHFFFAOYSA-N 5-[3-[4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl]propyl]-3-(4-methylphenyl)-1,2,4-oxadiazole Chemical compound C=12C(C)=C(C)SC2=NC=NC=1N(CC1)CCN1CCCC(ON=1)=NC=1C1=CC=C(C)C=C1 JKXHFLZXUGHMGM-UHFFFAOYSA-N 0.000 claims description 2
- LPMALGBKIXQXQN-UHFFFAOYSA-N 5-[3-[4-(6-ethylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl]propyl]-3-thiophen-2-yl-1,2,4-oxadiazole Chemical compound N1=CN=C2SC(CC)=CC2=C1N(CC1)CCN1CCCC(ON=1)=NC=1C1=CC=CS1 LPMALGBKIXQXQN-UHFFFAOYSA-N 0.000 claims description 2
- PEQHATYGQMKPDM-UHFFFAOYSA-N 6-[2-[4-(1-benzothiophen-4-yl)piperidin-1-yl]ethyl]-3,4-dihydro-1H-quinolin-2-one Chemical compound S1C2=C(C=C1)C(=CC=C2)C1CCN(CC1)CCC=1C=C2CCC(NC2=CC=1)=O PEQHATYGQMKPDM-UHFFFAOYSA-N 0.000 claims description 2
- DLYAUPSKDVMPSS-UHFFFAOYSA-N 6-[2-[4-(2-fluoro-1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-3,4-dihydro-1H-quinolin-2-one Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC=1C=C2CCC(NC2=CC=1)=O DLYAUPSKDVMPSS-UHFFFAOYSA-N 0.000 claims description 2
- WSXVVKWNMGLXPQ-UHFFFAOYSA-N 6-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC(=O)COC2=CC=C1CCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 WSXVVKWNMGLXPQ-UHFFFAOYSA-N 0.000 claims description 2
- BCQDQVRXJROXMU-UHFFFAOYSA-N 6-[4-[4-(2-fluoro-1-benzothiophen-4-yl)piperazin-1-yl]butyl]-3,4-dihydro-1H-quinolin-2-one Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCCCC=1C=C2CCC(NC2=CC=1)=O BCQDQVRXJROXMU-UHFFFAOYSA-N 0.000 claims description 2
- XRWBBZODDQFRNH-UHFFFAOYSA-N 6-ethyl-4-[4-(2-thiophen-2-ylethyl)piperazin-1-yl]thieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC(CC)=CC2=C1N(CC1)CCN1CCC1=CC=CS1 XRWBBZODDQFRNH-UHFFFAOYSA-N 0.000 claims description 2
- UUEZNMMASZDLDL-UHFFFAOYSA-N 7-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-1-benzyl-3-methylquinazoline-2,4-dione Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2C(N(C(N(C2=C1)CC1=CC=CC=C1)=O)C)=O UUEZNMMASZDLDL-UHFFFAOYSA-N 0.000 claims description 2
- TYXBCJTVAOMGMN-UHFFFAOYSA-N 7-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-3,4-dihydro-1H-quinoline-2-thione Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=C2CCC(NC2=C1)=S TYXBCJTVAOMGMN-UHFFFAOYSA-N 0.000 claims description 2
- SHNSKFRGOBKYIC-UHFFFAOYSA-N 7-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-3,4-dihydro-2H-1lambda6,2-benzothiazine 1,1-dioxide Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(CCNS2(=O)=O)C=C1 SHNSKFRGOBKYIC-UHFFFAOYSA-N 0.000 claims description 2
- GKXOICRHYDMLAH-UHFFFAOYSA-N 7-[2-[4-(2-fluoro-1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-3,4-dihydro-1H-quinolin-2-one Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=CC=C2CCC(NC2=C1)=O GKXOICRHYDMLAH-UHFFFAOYSA-N 0.000 claims description 2
- AMMXPFBHNDVVTP-UHFFFAOYSA-N 7-[2-[4-(3-methyl-1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-3,4-dihydro-1H-quinolin-2-one Chemical compound CC=1C2=C(SC=1)C=CC=C2N1CCN(CC1)CCC1=CC=C2CCC(NC2=C1)=O AMMXPFBHNDVVTP-UHFFFAOYSA-N 0.000 claims description 2
- KYUNAQGKQDNERM-UHFFFAOYSA-N 7-[2-[4-(6-fluoro-1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-3,4-dihydro-1H-quinolin-2-one Chemical compound FC=1C=C(C2=C(SC=C2)C=1)N1CCN(CC1)CCC1=CC=C2CCC(NC2=C1)=O KYUNAQGKQDNERM-UHFFFAOYSA-N 0.000 claims description 2
- LSWAIDPZAGTFNI-UHFFFAOYSA-N 9-hydroxy-2-methyl-3-[2-(4-thieno[2,3-c]pyridin-4-ylpiperazin-1-yl)ethyl]-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound OC1CCCN2C1=NC(=C(C2=O)CCN1CCN(CC1)C1=C2C(=CN=C1)SC=C2)C LSWAIDPZAGTFNI-UHFFFAOYSA-N 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- KCGVCOYGVSPQOS-UHFFFAOYSA-N C(C)(=O)N1C=C(C2=CC(=CC=C12)C#N)CCCCN1CCN(CC1)C1=CC=CC=2SC=CC=21 Chemical compound C(C)(=O)N1C=C(C2=CC(=CC=C12)C#N)CCCCN1CCN(CC1)C1=CC=CC=2SC=CC=21 KCGVCOYGVSPQOS-UHFFFAOYSA-N 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- WTPUPRUOBRKKPC-UHFFFAOYSA-N FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2O)C Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2O)C WTPUPRUOBRKKPC-UHFFFAOYSA-N 0.000 claims description 2
- KXLZVZNZPJCJEY-UHFFFAOYSA-N FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=CC2=C(NC(N2)=O)C=C1 Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=CC2=C(NC(N2)=O)C=C1 KXLZVZNZPJCJEY-UHFFFAOYSA-N 0.000 claims description 2
- IMICGKCVFIYIAJ-UHFFFAOYSA-N FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O IMICGKCVFIYIAJ-UHFFFAOYSA-N 0.000 claims description 2
- DUZUPNAFLZYFHR-UHFFFAOYSA-N FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=CC=CC=2N=C(SC=21)N Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=CC=CC=2N=C(SC=21)N DUZUPNAFLZYFHR-UHFFFAOYSA-N 0.000 claims description 2
- VZMIAIOZYJZWSQ-UHFFFAOYSA-N FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC=1C=C2C=CC(NC2=CC=1)=O Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC=1C=C2C=CC(NC2=CC=1)=O VZMIAIOZYJZWSQ-UHFFFAOYSA-N 0.000 claims description 2
- HYJWYFHGXACDIU-UHFFFAOYSA-N FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC=1C=CC2=C(N=C(S2)N)C=1 Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC=1C=CC2=C(N=C(S2)N)C=1 HYJWYFHGXACDIU-UHFFFAOYSA-N 0.000 claims description 2
- SDXFLKYHAUYOER-UHFFFAOYSA-N FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCCCCC1=CC=C2C=CC(NC2=C1)=O Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCCCCC1=CC=C2C=CC(NC2=C1)=O SDXFLKYHAUYOER-UHFFFAOYSA-N 0.000 claims description 2
- VPELKUVRUUVLLN-UHFFFAOYSA-N FC=1C=C(C2=C(SC=C2)C=1)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O Chemical compound FC=1C=C(C2=C(SC=C2)C=1)N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O VPELKUVRUUVLLN-UHFFFAOYSA-N 0.000 claims description 2
- NMUKRRWMCNXUIK-UHFFFAOYSA-N FC=1C=C(C2=C(SC=C2)C=1)N1CCN(CC1)CCCCCC1=CC=C2C=CC(NC2=C1)=O Chemical compound FC=1C=C(C2=C(SC=C2)C=1)N1CCN(CC1)CCCCCC1=CC=C2C=CC(NC2=C1)=O NMUKRRWMCNXUIK-UHFFFAOYSA-N 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- ILXUQZUEWABTGF-UHFFFAOYSA-N N-[4-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=CC2=C1N=C(S2)NC(C)=O ILXUQZUEWABTGF-UHFFFAOYSA-N 0.000 claims description 2
- VQLYGEWSCCJRMT-UHFFFAOYSA-N N-[5-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=CC2=C(N=C(S2)NC(C)=O)C=1 VQLYGEWSCCJRMT-UHFFFAOYSA-N 0.000 claims description 2
- CCVQXGISEIFUGW-UHFFFAOYSA-N N-[5-[2-[4-(2-fluoro-1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC2=CC(CCN3CCN(CC3)C3=C4C=C(F)SC4=CC=C3)=CC=C2S1 CCVQXGISEIFUGW-UHFFFAOYSA-N 0.000 claims description 2
- VTRDTHNGUFWMPX-UHFFFAOYSA-N N-[6-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(N=C(S2)NC(C)=O)C=C1 VTRDTHNGUFWMPX-UHFFFAOYSA-N 0.000 claims description 2
- YNJWRVGOMSONHN-UHFFFAOYSA-N N-[6-[2-[4-(2-fluoro-1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCN(CC1)CCC1=CC2=C(N=C(S2)NC(C)=O)C=C1 YNJWRVGOMSONHN-UHFFFAOYSA-N 0.000 claims description 2
- ZRFNUMBGYLIEMG-UHFFFAOYSA-N N-[7-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=CC=2N=C(SC=21)NC(C)=O ZRFNUMBGYLIEMG-UHFFFAOYSA-N 0.000 claims description 2
- LVADZGJNRRLPDK-UHFFFAOYSA-N N-[7-[2-[4-(2-fluoro-1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC2=CC=CC(CCN3CCN(CC3)C3=C4C=C(F)SC4=CC=C3)=C2S1 LVADZGJNRRLPDK-UHFFFAOYSA-N 0.000 claims description 2
- MFCRSJJVXNJHME-UHFFFAOYSA-N O=C1CCC2CCC(CCN3CCN(CC3)c3cncc4sccc34)CC2N1 Chemical compound O=C1CCC2CCC(CCN3CCN(CC3)c3cncc4sccc34)CC2N1 MFCRSJJVXNJHME-UHFFFAOYSA-N 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- HGGGQDUQWZFLPR-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)C1CCN(CC1)CCC1=CC2=C(OCC(N2)=O)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)C1CCN(CC1)CCC1=CC2=C(OCC(N2)=O)C=C1 HGGGQDUQWZFLPR-UHFFFAOYSA-N 0.000 claims description 2
- DMWOAPDORNWCNR-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)C1CCN(CC1)CCC1=CC=C2CCC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)C1CCN(CC1)CCC1=CC=C2CCC(NC2=C1)=O DMWOAPDORNWCNR-UHFFFAOYSA-N 0.000 claims description 2
- WJAJWDPSJIBVEJ-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)C1CCN(CC1)CCCCC=1C=C2CCC(NC2=CC=1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)C1CCN(CC1)CCCCC=1C=C2CCC(NC2=CC=1)=O WJAJWDPSJIBVEJ-UHFFFAOYSA-N 0.000 claims description 2
- IHLVTIRKNNUEDD-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC(=O)C1=CC2=C(NC(N2)=O)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC(=O)C1=CC2=C(NC(N2)=O)C=C1 IHLVTIRKNNUEDD-UHFFFAOYSA-N 0.000 claims description 2
- WGIKUKNZQXPLHX-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC(=O)C1=CC2=C(NC(S2)=O)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC(=O)C1=CC2=C(NC(S2)=O)C=C1 WGIKUKNZQXPLHX-UHFFFAOYSA-N 0.000 claims description 2
- ALBJLVZIWQKCKN-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC(=O)C1=CC=C2CCC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC(=O)C1=CC=C2CCC(NC2=C1)=O ALBJLVZIWQKCKN-UHFFFAOYSA-N 0.000 claims description 2
- KMFFUZXGXHASQB-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC(O)C1=CC=C2C=CC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC(O)C1=CC=C2C=CC(NC2=C1)=O KMFFUZXGXHASQB-UHFFFAOYSA-N 0.000 claims description 2
- ZPLLNVVOWOSBOJ-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC1=CC(NC2=CC=CC=C12)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC1=CC(NC2=CC=CC=C12)=O ZPLLNVVOWOSBOJ-UHFFFAOYSA-N 0.000 claims description 2
- XBCPNDIHKPAVPX-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC1=CN(C2=CC=CC=C12)C Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC1=CN(C2=CC=CC=C12)C XBCPNDIHKPAVPX-UHFFFAOYSA-N 0.000 claims description 2
- UDRYBMBEXSTHNJ-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC1=NC2=C(N1)C=CC=C2 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CC1=NC2=C(N1)C=CC=C2 UDRYBMBEXSTHNJ-UHFFFAOYSA-N 0.000 claims description 2
- KBOFZHXMNBYFFH-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=CS1)C Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=CS1)C KBOFZHXMNBYFFH-UHFFFAOYSA-N 0.000 claims description 2
- OCHIEZWGIHOVEQ-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(N(C(N2)=O)C)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(N(C(N2)=O)C)C=C1 OCHIEZWGIHOVEQ-UHFFFAOYSA-N 0.000 claims description 2
- NFPWRHWDAIDXGI-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(N=C(S2)N)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(N=C(S2)N)C=C1 NFPWRHWDAIDXGI-UHFFFAOYSA-N 0.000 claims description 2
- YLQGFTVGNDSATF-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(N=C(S2)NC(OCCCCC)=O)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(N=C(S2)NC(OCCCCC)=O)C=C1 YLQGFTVGNDSATF-UHFFFAOYSA-N 0.000 claims description 2
- JKFGWCQWZHWMED-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(N=CS2)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(N=CS2)C=C1 JKFGWCQWZHWMED-UHFFFAOYSA-N 0.000 claims description 2
- LYIVOAYWRLVRGJ-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(NC(O2)=O)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(NC(O2)=O)C=C1 LYIVOAYWRLVRGJ-UHFFFAOYSA-N 0.000 claims description 2
- CHESAJJJIGYAHM-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=CC2=C1N=C(S2)N Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=CC2=C1N=C(S2)N CHESAJJJIGYAHM-UHFFFAOYSA-N 0.000 claims description 2
- CVXZPSGNMNHGGT-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=CC=2N=C(SC=21)N Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC=CC=2N=C(SC=21)N CVXZPSGNMNHGGT-UHFFFAOYSA-N 0.000 claims description 2
- HFMCDRFECVDJHU-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CN(C2=CC=C(C=C12)C#N)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CN(C2=CC=C(C=C12)C#N)S(=O)(=O)C1=CC=C(C)C=C1 HFMCDRFECVDJHU-UHFFFAOYSA-N 0.000 claims description 2
- XYQSOHGAGJKHNZ-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CN(C2=CC=C(C=C12)OC)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CN(C2=CC=C(C=C12)OC)S(=O)(=O)C1=CC=C(C)C=C1 XYQSOHGAGJKHNZ-UHFFFAOYSA-N 0.000 claims description 2
- FIBONCALDRDINS-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CNC2=CC=C(C=C12)C#N Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CNC2=CC=C(C=C12)C#N FIBONCALDRDINS-UHFFFAOYSA-N 0.000 claims description 2
- MURAVVBTKTXEPR-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CNC2=CC=C(C=C12)OC Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CNC2=CC=C(C=C12)OC MURAVVBTKTXEPR-UHFFFAOYSA-N 0.000 claims description 2
- UZTBSHCUQSJWIH-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=NC(=C(C(N1)=O)CC)CC Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=NC(=C(C(N1)=O)CC)CC UZTBSHCUQSJWIH-UHFFFAOYSA-N 0.000 claims description 2
- WZSMEROZTZJJDA-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=NC2=C(N1)C=CC=C2 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=NC2=C(N1)C=CC=C2 WZSMEROZTZJJDA-UHFFFAOYSA-N 0.000 claims description 2
- ILGUDRDZORTZQT-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=NC=CC(N1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=NC=CC(N1)=O ILGUDRDZORTZQT-UHFFFAOYSA-N 0.000 claims description 2
- TUVXDPMBDGZXNH-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=C2C(NC(=NC2=CC=1)C)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=C2C(NC(=NC2=CC=1)C)=O TUVXDPMBDGZXNH-UHFFFAOYSA-N 0.000 claims description 2
- HOZYHOBFBUSOCI-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=C2CC(NC2=CC=1)=S Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=C2CC(NC2=CC=1)=S HOZYHOBFBUSOCI-UHFFFAOYSA-N 0.000 claims description 2
- ZBSRYKJVUYVUPV-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=C2CCC(NC2=CC=1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=C2CCC(NC2=CC=1)=O ZBSRYKJVUYVUPV-UHFFFAOYSA-N 0.000 claims description 2
- LDNCVCFYLQMLCR-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=CC2=C(N(C(N2)=O)C)C=1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=CC2=C(N(C(N2)=O)C)C=1 LDNCVCFYLQMLCR-UHFFFAOYSA-N 0.000 claims description 2
- AMCGNHPMLVBAQK-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=CC2=C(N=C(S2)N)C=1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=CC2=C(N=C(S2)N)C=1 AMCGNHPMLVBAQK-UHFFFAOYSA-N 0.000 claims description 2
- PSAQSKNXPFXQJH-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCC1=CN(C2=CC=C(C=C12)OC)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCC1=CN(C2=CC=C(C=C12)OC)S(=O)(=O)C1=CC=C(C)C=C1 PSAQSKNXPFXQJH-UHFFFAOYSA-N 0.000 claims description 2
- JTDLIQGTHPBQQA-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCC1=CNC2=CC=C(C=C12)C#N Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCC1=CNC2=CC=C(C=C12)C#N JTDLIQGTHPBQQA-UHFFFAOYSA-N 0.000 claims description 2
- CCNVEDVQZFNLHB-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCC1=CNC2=CC=C(C=C12)OC Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCC1=CNC2=CC=C(C=C12)OC CCNVEDVQZFNLHB-UHFFFAOYSA-N 0.000 claims description 2
- KOVXRWMIAMPQMJ-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC(=O)C1=CC=C2C=CC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC(=O)C1=CC=C2C=CC(NC2=C1)=O KOVXRWMIAMPQMJ-UHFFFAOYSA-N 0.000 claims description 2
- OOWVNYTWZHMYDX-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC(=O)C1=CC=C2CCC(NC2=C1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC(=O)C1=CC=C2CCC(NC2=C1)=O OOWVNYTWZHMYDX-UHFFFAOYSA-N 0.000 claims description 2
- KVZIUZMKSGBHIG-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CN(C2=CC=C(C=C12)OC)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CN(C2=CC=C(C=C12)OC)S(=O)(=O)C1=CC=C(C)C=C1 KVZIUZMKSGBHIG-UHFFFAOYSA-N 0.000 claims description 2
- AJCBTMQLMBVUBO-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CNC2=CC=C(C=C12)C#N Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CNC2=CC=C(C=C12)C#N AJCBTMQLMBVUBO-UHFFFAOYSA-N 0.000 claims description 2
- BNXCPAVJSMMVPU-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CNC2=CC=C(C=C12)OC Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=CNC2=CC=C(C=C12)OC BNXCPAVJSMMVPU-UHFFFAOYSA-N 0.000 claims description 2
- DHSGTYMTXPSIEB-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=COC2=CC(=C(C=C2C1=O)OC)OC Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=COC2=CC(=C(C=C2C1=O)OC)OC DHSGTYMTXPSIEB-UHFFFAOYSA-N 0.000 claims description 2
- LGNQDGZEDYGQHO-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=NN=NN1C1CCCCC1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC1=NN=NN1C1CCCCC1 LGNQDGZEDYGQHO-UHFFFAOYSA-N 0.000 claims description 2
- XALOLRQAFYQIOX-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC=1C=C2CCC(NC2=CC=1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCC=1C=C2CCC(NC2=CC=1)=O XALOLRQAFYQIOX-UHFFFAOYSA-N 0.000 claims description 2
- IGCZJTCYRQEIDP-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCCC=1C=C2C(NC=NC2=CC=1)=O Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCCCCC=1C=C2C(NC=NC2=CC=1)=O IGCZJTCYRQEIDP-UHFFFAOYSA-N 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 claims description 2
- 208000026345 acute stress disease Diseases 0.000 claims description 2
- 230000003044 adaptive effect Effects 0.000 claims description 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 2
- 230000003542 behavioural effect Effects 0.000 claims description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 claims description 2
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 claims description 2
- 125000005058 dihydrotriazolyl group Chemical group N1(NNC=C1)* 0.000 claims description 2
- 230000002996 emotional effect Effects 0.000 claims description 2
- 201000003104 endogenous depression Diseases 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- CRRWMSRYYSLEBJ-UHFFFAOYSA-N naphthalen-1-yl benzenesulfonate Chemical compound C=1C=CC2=CC=CC=C2C=1OS(=O)(=O)C1=CC=CC=C1 CRRWMSRYYSLEBJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 208000007442 rickets Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 208000016686 tic disease Diseases 0.000 claims description 2
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 claims description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- 206010002942 Apathy Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- XTGFBAKILGLSAX-UHFFFAOYSA-N N-azido-N-ethylethanamine Chemical compound CCN(CC)N=[N+]=[N-] XTGFBAKILGLSAX-UHFFFAOYSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 209
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 208
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 105
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 98
- 239000000047 product Substances 0.000 description 97
- 239000007787 solid Substances 0.000 description 93
- 235000019439 ethyl acetate Nutrition 0.000 description 90
- 239000000203 mixture Substances 0.000 description 90
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 81
- 239000000243 solution Substances 0.000 description 78
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 76
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 74
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 68
- 239000011541 reaction mixture Substances 0.000 description 66
- 238000005160 1H NMR spectroscopy Methods 0.000 description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 55
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 46
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 37
- 229910000027 potassium carbonate Inorganic materials 0.000 description 37
- 235000011181 potassium carbonates Nutrition 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 239000012065 filter cake Substances 0.000 description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- 238000004440 column chromatography Methods 0.000 description 29
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- 239000005457 ice water Substances 0.000 description 28
- 239000002904 solvent Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 24
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 22
- 238000010992 reflux Methods 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000002585 base Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 18
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- 239000012043 crude product Substances 0.000 description 14
- 238000010828 elution Methods 0.000 description 13
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 8
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- 230000008485 antagonism Effects 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 229940043279 diisopropylamine Drugs 0.000 description 8
- 229960003638 dopamine Drugs 0.000 description 8
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 8
- 235000009518 sodium iodide Nutrition 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- JKVUGXRJSYRXFN-UHFFFAOYSA-N 3-(2-chloroethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound OC1CCCN2C(=O)C(CCCl)=C(C)N=C21 JKVUGXRJSYRXFN-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 230000008484 agonism Effects 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 239000007810 chemical reaction solvent Substances 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000001270 agonistic effect Effects 0.000 description 5
- 238000007098 aminolysis reaction Methods 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 235000011118 potassium hydroxide Nutrition 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- DOHOILFXOMBVDR-UHFFFAOYSA-N 5-chloro-6-(2-chloroethyl)-1,3-dihydroinden-2-one Chemical compound C1=C(Cl)C(CCCl)=CC2=C1CC(=O)C2 DOHOILFXOMBVDR-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000000164 antipsychotic agent Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical class ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 4
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 0 *CCCCc1ccc(CCC(N2)=O)c2c1 Chemical compound *CCCCc1ccc(CCC(N2)=O)c2c1 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- 239000007818 Grignard reagent Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003491 cAMP production Effects 0.000 description 3
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical class C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005660 chlorination reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 3
- 150000004795 grignard reagents Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 230000008925 spontaneous activity Effects 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- QDFKKJYEIFBEFC-UHFFFAOYSA-N 1-bromo-3-fluorobenzene Chemical compound FC1=CC=CC(Br)=C1 QDFKKJYEIFBEFC-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FAFGMAGIYHHRKN-UHFFFAOYSA-N 2-diphenylphosphanylethyl(diphenyl)phosphane;palladium Chemical compound [Pd].C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 FAFGMAGIYHHRKN-UHFFFAOYSA-N 0.000 description 2
- CMWCQQUYLPYOMY-UHFFFAOYSA-N 3-(2-chloroethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound C1CCCN2C(=O)C(CCCl)=C(C)N=C21 CMWCQQUYLPYOMY-UHFFFAOYSA-N 0.000 description 2
- BKAWJIRCKVUVED-UHFFFAOYSA-N 5-(2-hydroxyethyl)-4-methylthiazole Chemical compound CC=1N=CSC=1CCO BKAWJIRCKVUVED-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- PUNWHJMKQNNINR-UHFFFAOYSA-N CS(=O)(=O)OCCC1=C(C=C2CCC(NC2=C1)=O)Cl Chemical compound CS(=O)(=O)OCCC1=C(C=C2CCC(NC2=C1)=O)Cl PUNWHJMKQNNINR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 238000003747 Grignard reaction Methods 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 238000007126 N-alkylation reaction Methods 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000011938 amidation process Methods 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical compound CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940112669 cuprous oxide Drugs 0.000 description 2
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- MJPUHPKVTAZJOZ-UHFFFAOYSA-N ethyl 2-ethyl-3-oxopentanoate Chemical compound CCOC(=O)C(CC)C(=O)CC MJPUHPKVTAZJOZ-UHFFFAOYSA-N 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- DGGJQLCAYQCPDD-UHFFFAOYSA-N methyl 2-aminothiophene-3-carboxylate Chemical compound COC(=O)C=1C=CSC=1N DGGJQLCAYQCPDD-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- CRWVOXFUXPYTRK-UHFFFAOYSA-N pent-4-yn-1-ol Chemical compound OCCCC#C CRWVOXFUXPYTRK-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical class ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940075930 picrate Drugs 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ASQOQJYHIYYTEJ-GBESFXJTSA-N (1r,7s,9as)-7-decyl-2,3,4,6,7,8,9,9a-octahydro-1h-quinolizin-1-ol Chemical compound O[C@@H]1CCCN2C[C@@H](CCCCCCCCCC)CC[C@H]21 ASQOQJYHIYYTEJ-GBESFXJTSA-N 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- XDUUWPNOUUQXBX-UHFFFAOYSA-N 1-(1-benzothiophen-4-yl)piperazine;hydrochloride Chemical compound Cl.C1CNCCN1C1=CC=CC2=C1C=CS2 XDUUWPNOUUQXBX-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- YAYOVHRLVOHYMW-UHFFFAOYSA-N 1h-pyrimidin-6-one;hydrochloride Chemical compound Cl.O=C1C=CN=CN1 YAYOVHRLVOHYMW-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical class CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- HZOUMYYUDFUDPB-UHFFFAOYSA-N 2-(1h-indol-3-yl)ethyl methanesulfonate Chemical compound C1=CC=C2C(CCOS(=O)(=O)C)=CNC2=C1 HZOUMYYUDFUDPB-UHFFFAOYSA-N 0.000 description 1
- PTIKWIVMTSZZFR-UHFFFAOYSA-N 2-(2-chloroethyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCl)=NC(=O)C2=C1 PTIKWIVMTSZZFR-UHFFFAOYSA-N 0.000 description 1
- WVBRBOFTWPPIPT-UHFFFAOYSA-N 2-(2-oxo-1H-quinolin-7-yl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1=CC=C2C=CC(NC2=C1)=O WVBRBOFTWPPIPT-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- OACPOWYLLGHGCR-UHFFFAOYSA-N 2-chloro-6-fluorobenzaldehyde Chemical compound FC1=CC=CC(Cl)=C1C=O OACPOWYLLGHGCR-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- CEBDXRXVGUQZJK-UHFFFAOYSA-N 2-methyl-1-benzofuran-7-carboxylic acid Chemical compound C1=CC(C(O)=O)=C2OC(C)=CC2=C1 CEBDXRXVGUQZJK-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical class CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- ZKUYSJHXBFFGPU-UHFFFAOYSA-N 2516-95-2 Chemical compound OC(=O)C1=CC(Cl)=CC=C1[N+]([O-])=O ZKUYSJHXBFFGPU-UHFFFAOYSA-N 0.000 description 1
- DNNVRTZJRKIUFK-UHFFFAOYSA-N 3,4-dihydroquinoline Chemical compound C1=CC=C2N=CCCC2=C1 DNNVRTZJRKIUFK-UHFFFAOYSA-N 0.000 description 1
- SOSPMXMEOFGPIM-UHFFFAOYSA-N 3,5-dibromopyridine Chemical compound BrC1=CN=CC(Br)=C1 SOSPMXMEOFGPIM-UHFFFAOYSA-N 0.000 description 1
- DFZLZGAIWJGCIJ-UHFFFAOYSA-N 3-(2-chloroethyl)-2-methyl-9-phenylmethoxypyrido[1,2-a]pyrimidin-4-one Chemical compound C=1C=CN2C(=O)C(CCCl)=C(C)N=C2C=1OCC1=CC=CC=C1 DFZLZGAIWJGCIJ-UHFFFAOYSA-N 0.000 description 1
- LFTGLYCNMGGMKL-UHFFFAOYSA-N 3-(2-chloroethyl)-2-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC=CN2C(=O)C(CCCl)=C(C)N=C21 LFTGLYCNMGGMKL-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- XMFRRROSDAWYLB-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)CCCC2)C XMFRRROSDAWYLB-UHFFFAOYSA-N 0.000 description 1
- FQKULTHPCINDHU-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-9,9-difluoro-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4-one hydrochloride Chemical compound Cl.Cc1nc2n(CCCC2(F)F)c(=O)c1CCN1CCN(CC1)c1cccc2sccc12 FQKULTHPCINDHU-UHFFFAOYSA-N 0.000 description 1
- CZRFPOUYJLPGGN-UHFFFAOYSA-N 3-[2-[4-(1-benzothiophen-4-yl)piperazin-1-yl]ethyl]-9-hydroxy-2,9-dimethyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4-one hydrochloride Chemical compound Cl.Cc1nc2n(CCCC2(C)O)c(=O)c1CCN1CCN(CC1)c1cccc2sccc12 CZRFPOUYJLPGGN-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- QRPNDOFSVHOGCK-UHFFFAOYSA-N 3-di(propan-2-yl)phosphanylpropyl-di(propan-2-yl)phosphane Chemical compound CC(C)P(C(C)C)CCCP(C(C)C)C(C)C QRPNDOFSVHOGCK-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- UIADWSXPNFQQCZ-UHFFFAOYSA-N 4-[4-(3,4-dichlorophenyl)-5-phenyl-1,3-oxazol-2-yl]butanoic acid Chemical compound ClC=1C=C(C=CC=1Cl)C=1N=C(OC=1C1=CC=CC=C1)CCCC(=O)O UIADWSXPNFQQCZ-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- GTFMIJNXNMDHAB-UHFFFAOYSA-N 4h-1,4-benzothiazin-3-one Chemical compound C1=CC=C2NC(=O)CSC2=C1 GTFMIJNXNMDHAB-UHFFFAOYSA-N 0.000 description 1
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 1
- ZTISXEUUBAHHQV-UHFFFAOYSA-N 5-(2-chloroethyl)-1,3-dihydrobenzimidazol-2-one Chemical compound ClCCC1=CC=C2NC(=O)NC2=C1 ZTISXEUUBAHHQV-UHFFFAOYSA-N 0.000 description 1
- NZWVWWSZPMJHHW-UHFFFAOYSA-N 5-(4-oxo-3H-quinazolin-6-yl)pentyl methanesulfonate Chemical compound CS(=O)(=O)OCCCCCC=1C=C2C(NC=NC2=CC=1)=O NZWVWWSZPMJHHW-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- KKNZNYQQZOBEKI-UHFFFAOYSA-N 6-(2-chloroethyl)-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=CC(CCCl)=CC=C21 KKNZNYQQZOBEKI-UHFFFAOYSA-N 0.000 description 1
- NYZNJWXJFPFINK-UHFFFAOYSA-N 6-(2-chloroethyl)-4h-1,4-benzothiazin-3-one Chemical compound S1CC(=O)NC2=CC(CCCl)=CC=C21 NYZNJWXJFPFINK-UHFFFAOYSA-N 0.000 description 1
- HQNXRLDPFHKTGQ-UHFFFAOYSA-N 6-(2-chloroethyl)-4h-1,4-benzoxazin-3-one Chemical compound O1CC(=O)NC2=CC(CCCl)=CC=C21 HQNXRLDPFHKTGQ-UHFFFAOYSA-N 0.000 description 1
- ZGHCGIDMQSHUAZ-UHFFFAOYSA-N 6-(5-chloropentyl)-2-methyl-3H-quinazolin-4-one Chemical compound ClCCCCCC=1C=C2C(NC(=NC2=CC=1)C)=O ZGHCGIDMQSHUAZ-UHFFFAOYSA-N 0.000 description 1
- KSEQSFLKQWTSMG-UHFFFAOYSA-N 7-(2-chloroethyl)-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)CCCC2=CC(CCCl)=CC=C21 KSEQSFLKQWTSMG-UHFFFAOYSA-N 0.000 description 1
- LKLSFDWYIBUGNT-UHFFFAOYSA-N 7-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=CC(O)=CC=C21 LKLSFDWYIBUGNT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- LXTOUGSYIZTYOC-UHFFFAOYSA-N C(C)C=1N=C(N(C(C=1CC)=O)C(=O)OC(C)(C)C)CCOS(=O)(=O)C Chemical compound C(C)C=1N=C(N(C(C=1CC)=O)C(=O)OC(C)(C)C)CCOS(=O)(=O)C LXTOUGSYIZTYOC-UHFFFAOYSA-N 0.000 description 1
- HFGUINASBGDWLY-UHFFFAOYSA-N C(C1)NCCN1c1c(cc[s]2)c2ncn1 Chemical compound C(C1)NCCN1c1c(cc[s]2)c2ncn1 HFGUINASBGDWLY-UHFFFAOYSA-N 0.000 description 1
- FYFDSCBLPXXVMZ-UHFFFAOYSA-N C1C(c2c(cc[s]3)c3ccc2)=CCNC1 Chemical compound C1C(c2c(cc[s]3)c3ccc2)=CCNC1 FYFDSCBLPXXVMZ-UHFFFAOYSA-N 0.000 description 1
- AYWLMPAEIWRCEN-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(c1c(cc[s]2)c2ccc1)O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(c1c(cc[s]2)c2ccc1)O)=O AYWLMPAEIWRCEN-UHFFFAOYSA-N 0.000 description 1
- GKKPNTXHFNLZQV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1c(cc[s]2)c2ncn1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1c(cc[s]2)c2ncn1)=O GKKPNTXHFNLZQV-UHFFFAOYSA-N 0.000 description 1
- WMCARZAOGYXQPC-UHFFFAOYSA-N CC1(CCCCCCCCC1)N Chemical compound CC1(CCCCCCCCC1)N WMCARZAOGYXQPC-UHFFFAOYSA-N 0.000 description 1
- PKDRHVKYJMENDE-UHFFFAOYSA-N CC1(CCCCCCCCCCC1)N Chemical compound CC1(CCCCCCCCCCC1)N PKDRHVKYJMENDE-UHFFFAOYSA-N 0.000 description 1
- IGTUAEAMHQJRGY-UHFFFAOYSA-N CCOC(c([s]c1ccc2C)cc1c2Br)=O Chemical compound CCOC(c([s]c1ccc2C)cc1c2Br)=O IGTUAEAMHQJRGY-UHFFFAOYSA-N 0.000 description 1
- MIYPMUJFZIKLKG-UHFFFAOYSA-N CS(=O)(=O)OCCC1=C(C=C2C=CC(NC2=C1)=O)Cl Chemical compound CS(=O)(=O)OCCC1=C(C=C2C=CC(NC2=C1)=O)Cl MIYPMUJFZIKLKG-UHFFFAOYSA-N 0.000 description 1
- WFANRIGXDGXSIW-UHFFFAOYSA-N CS(=O)(=O)OCCC1=CC=C2CCC(NC2=C1)=O Chemical compound CS(=O)(=O)OCCC1=CC=C2CCC(NC2=C1)=O WFANRIGXDGXSIW-UHFFFAOYSA-N 0.000 description 1
- OQWILLDIAIQLNB-UHFFFAOYSA-N CS(=O)(=O)OCCC=1N(C(C=CN=1)=O)C(=O)OC(C)(C)C Chemical compound CS(=O)(=O)OCCC=1N(C(C=CN=1)=O)C(=O)OC(C)(C)C OQWILLDIAIQLNB-UHFFFAOYSA-N 0.000 description 1
- PXMLDIZUQJPXKL-UHFFFAOYSA-N CS(=O)(=O)OCCCC1=CC=C2C=CC(NC2=C1)=O Chemical compound CS(=O)(=O)OCCCC1=CC=C2C=CC(NC2=C1)=O PXMLDIZUQJPXKL-UHFFFAOYSA-N 0.000 description 1
- UYYSPSXCRVHKMO-UHFFFAOYSA-N CS(=O)(=O)OCCCC1=CC=C2CCC(NC2=C1)=O Chemical compound CS(=O)(=O)OCCCC1=CC=C2CCC(NC2=C1)=O UYYSPSXCRVHKMO-UHFFFAOYSA-N 0.000 description 1
- XKSIIZHVAANWMP-UHFFFAOYSA-N CS(=O)(=O)OCCCCC1=CC=C2C=CC(NC2=C1)=O Chemical compound CS(=O)(=O)OCCCCC1=CC=C2C=CC(NC2=C1)=O XKSIIZHVAANWMP-UHFFFAOYSA-N 0.000 description 1
- UMFYGTIACZAOJM-UHFFFAOYSA-N CS(=O)(=O)OCCCCC1=CC=C2CCC(NC2=C1)=O Chemical compound CS(=O)(=O)OCCCCC1=CC=C2CCC(NC2=C1)=O UMFYGTIACZAOJM-UHFFFAOYSA-N 0.000 description 1
- CNTOODGTTHTYMV-UHFFFAOYSA-N CS(=O)(=O)OCCCCCC1=CC=C2C=CC(NC2=C1)=O Chemical compound CS(=O)(=O)OCCCCCC1=CC=C2C=CC(NC2=C1)=O CNTOODGTTHTYMV-UHFFFAOYSA-N 0.000 description 1
- XPCLFQMJIQOXOC-UHFFFAOYSA-N CS(=O)(=O)OCCCCCC1=CC=C2CCC(NC2=C1)=O Chemical compound CS(=O)(=O)OCCCCCC1=CC=C2CCC(NC2=C1)=O XPCLFQMJIQOXOC-UHFFFAOYSA-N 0.000 description 1
- 238000003148 Calcium 5 Assay Kit Methods 0.000 description 1
- HORDCPFFRDZLRG-UHFFFAOYSA-N Cc(c(Br)c1C=O)ccc1F Chemical compound Cc(c(Br)c1C=O)ccc1F HORDCPFFRDZLRG-UHFFFAOYSA-N 0.000 description 1
- ZRCPVCFKNJSSGJ-UHFFFAOYSA-N Cc1ccc2[s]ccc2c1Br Chemical compound Cc1ccc2[s]ccc2c1Br ZRCPVCFKNJSSGJ-UHFFFAOYSA-N 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- VKJBWJKWVCEDQS-UHFFFAOYSA-N Cl.FC1=CC2=C(S1)C=CC=C2N2CCN(CC2)CCCCCC2=CC=C1C=CC(NC1=C2)=O Chemical compound Cl.FC1=CC2=C(S1)C=CC=C2N2CCN(CC2)CCCCCC2=CC=C1C=CC(NC1=C2)=O VKJBWJKWVCEDQS-UHFFFAOYSA-N 0.000 description 1
- WWILMPCNFZFABA-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)C=2CCNCC2 Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)C=2CCNCC2 WWILMPCNFZFABA-UHFFFAOYSA-N 0.000 description 1
- BJHJGUCCAAXYJV-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)C=CC=C2OCC1=CC=CC=C1)C Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=C(N=C2N(C1=O)C=CC=C2OCC1=CC=CC=C1)C BJHJGUCCAAXYJV-UHFFFAOYSA-N 0.000 description 1
- QDFFWINAUMSHKF-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=C2CC(NC2=CC=1)=S Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC=1C=C2CC(NC2=CC=1)=S QDFFWINAUMSHKF-UHFFFAOYSA-N 0.000 description 1
- XZIWLJQTIREZFR-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=C(N=CS2)C Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=C(N=CS2)C XZIWLJQTIREZFR-UHFFFAOYSA-N 0.000 description 1
- GLGKZJCDBRTPJL-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=CC1=C(NC(S1)=O)C=C2 Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=CC1=C(NC(S1)=O)C=C2 GLGKZJCDBRTPJL-UHFFFAOYSA-N 0.000 description 1
- RLESELCJKDGIOO-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=CC1=C(OCC(N1)=O)C=C2 Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=CC1=C(OCC(N1)=O)C=C2 RLESELCJKDGIOO-UHFFFAOYSA-N 0.000 description 1
- NRMITJQNWUHJLH-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=NC(=C(C(N2)=O)CC)CC Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=NC(=C(C(N2)=O)CC)CC NRMITJQNWUHJLH-UHFFFAOYSA-N 0.000 description 1
- GXEWHEIMCVIDLJ-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=NC=CC(N2)=O Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC2=NC=CC(N2)=O GXEWHEIMCVIDLJ-UHFFFAOYSA-N 0.000 description 1
- QUBVOBFTGWEIGZ-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC=2C=C1CCC(NC1=CC2)=O Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCC=2C=C1CCC(NC1=CC2)=O QUBVOBFTGWEIGZ-UHFFFAOYSA-N 0.000 description 1
- BFEXINJNCBDYFB-UHFFFAOYSA-N Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCCCCC=2C=C1C(NC=NC1=CC2)=O Chemical compound Cl.S1C2=C(C=C1)C(=CC=C2)N2CCN(CC2)CCCCCC=2C=C1C(NC=NC1=CC2)=O BFEXINJNCBDYFB-UHFFFAOYSA-N 0.000 description 1
- WKQPJLRONVENGQ-UHFFFAOYSA-N Cl.S1C2=C(CC1)C(=CC=C2)N2CCNCC2 Chemical compound Cl.S1C2=C(CC1)C(=CC=C2)N2CCNCC2 WKQPJLRONVENGQ-UHFFFAOYSA-N 0.000 description 1
- YDFPFKMGQVYEKN-UHFFFAOYSA-N ClC1=CC2=C(S1)C=CC=C2N1CCNCC1 Chemical compound ClC1=CC2=C(S1)C=CC=C2N1CCNCC1 YDFPFKMGQVYEKN-UHFFFAOYSA-N 0.000 description 1
- ZTMGXVJRYBXGRI-UHFFFAOYSA-N ClCCC1=C(N=C2N(C1=O)CCC=C2)C Chemical compound ClCCC1=C(N=C2N(C1=O)CCC=C2)C ZTMGXVJRYBXGRI-UHFFFAOYSA-N 0.000 description 1
- BVSWEJYDGDWLSU-UHFFFAOYSA-N ClCCC1=C(N=C2N(C1=O)CCCC2F)C Chemical compound ClCCC1=C(N=C2N(C1=O)CCCC2F)C BVSWEJYDGDWLSU-UHFFFAOYSA-N 0.000 description 1
- GMFAHBHFBRVCFM-UHFFFAOYSA-N ClCCC1=CC2=C(NC(S2)=O)C=C1 Chemical compound ClCCC1=CC2=C(NC(S2)=O)C=C1 GMFAHBHFBRVCFM-UHFFFAOYSA-N 0.000 description 1
- NZUYGWKLUGOKMD-UHFFFAOYSA-N ClCCC=1C=C2CN(C(NC2=CC=1)=O)C Chemical compound ClCCC=1C=C2CN(C(NC2=CC=1)=O)C NZUYGWKLUGOKMD-UHFFFAOYSA-N 0.000 description 1
- NZCRUBBNZGVREM-UHFFFAOYSA-N Clc1c(cc[s]2)c2ncn1 Chemical compound Clc1c(cc[s]2)c2ncn1 NZCRUBBNZGVREM-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- TWLLPUMZVVGILS-UHFFFAOYSA-N Ethyl 2-aminobenzoate Chemical compound CCOC(=O)C1=CC=CC=C1N TWLLPUMZVVGILS-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- BUTAPHYKCHXFDQ-UHFFFAOYSA-N FC(C(=O)O)(F)F.N1(CCNCC1)C1=C2C(=CN=C1)SC=C2 Chemical compound FC(C(=O)O)(F)F.N1(CCNCC1)C1=C2C(=CN=C1)SC=C2 BUTAPHYKCHXFDQ-UHFFFAOYSA-N 0.000 description 1
- DWRCXWIMQUGJJQ-UHFFFAOYSA-N FC(C(=O)O)(F)F.N1(CCNCC1)C=1C2=C(N=CN1)SC=C2 Chemical compound FC(C(=O)O)(F)F.N1(CCNCC1)C=1C2=C(N=CN1)SC=C2 DWRCXWIMQUGJJQ-UHFFFAOYSA-N 0.000 description 1
- HEOCDBYYWHGPCD-UHFFFAOYSA-N FC(C(=O)O)(F)F.S1C2=C(C=C1)C(=CC=C2)C2CCNCC2 Chemical compound FC(C(=O)O)(F)F.S1C2=C(C=C1)C(=CC=C2)C2CCNCC2 HEOCDBYYWHGPCD-UHFFFAOYSA-N 0.000 description 1
- JIFWLWCLBUTEGP-UHFFFAOYSA-N FC1=CC2=C(S1)C=CC=C2N1CCNCC1 Chemical compound FC1=CC2=C(S1)C=CC=C2N1CCNCC1 JIFWLWCLBUTEGP-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- ULMHMJAEGZPQRY-UHFFFAOYSA-N N-(tert-butoxycarbonyl)piperidin-2-one Chemical compound CC(C)(C)OC(=O)N1CCCCC1=O ULMHMJAEGZPQRY-UHFFFAOYSA-N 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JWIPGAFCGUDKEY-UHFFFAOYSA-L O[Cr](Cl)(=O)=O.C1=CC=NC=C1 Chemical compound O[Cr](Cl)(=O)=O.C1=CC=NC=C1 JWIPGAFCGUDKEY-UHFFFAOYSA-L 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- JEDVKUHCDPPWNR-UHFFFAOYSA-N Oc1c(cc[s]2)c2ncn1 Chemical compound Oc1c(cc[s]2)c2ncn1 JEDVKUHCDPPWNR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- JUDRYUBHCDSXGX-UHFFFAOYSA-N S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(SCC(N2)=O)C=C1 Chemical compound S1C2=C(C=C1)C(=CC=C2)N1CCN(CC1)CCC1=CC2=C(SCC(N2)=O)C=C1 JUDRYUBHCDSXGX-UHFFFAOYSA-N 0.000 description 1
- ZQPVRDFINPZVAW-UHFFFAOYSA-N S1C=CC=2C1=CN=CC=2N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O Chemical compound S1C=CC=2C1=CN=CC=2N1CCN(CC1)CCC1=CC=C2C=CC(NC2=C1)=O ZQPVRDFINPZVAW-UHFFFAOYSA-N 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- LYPCGXKCQDYTFV-UHFFFAOYSA-N alpha-methylserotonin Chemical compound C1=C(O)C=C2C(CC(N)C)=CNC2=C1 LYPCGXKCQDYTFV-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical group [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- OTJZCIYGRUNXTP-UHFFFAOYSA-N but-3-yn-1-ol Chemical compound OCCC#C OTJZCIYGRUNXTP-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- FXORZKOZOQWVMQ-UHFFFAOYSA-L dichloropalladium;triphenylphosphane Chemical compound Cl[Pd]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FXORZKOZOQWVMQ-UHFFFAOYSA-L 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- ZZTSQZQUWBFTAT-UHFFFAOYSA-N diethylcyanamide Chemical compound CCN(CC)C#N ZZTSQZQUWBFTAT-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical class CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000005290 ethynyloxy group Chemical group C(#C)O* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- BVJUXXYBIMHHDW-UHFFFAOYSA-N iodane Chemical compound I.I BVJUXXYBIMHHDW-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004718 n-hexylthio group Chemical group C(CCCCC)S* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- GFNAXQJAAAXIQF-UHFFFAOYSA-N phenyl-[1-(2-phenylphosphanylnaphthalen-1-yl)naphthalen-2-yl]phosphane Chemical group C=1C=C2C=CC=CC2=C(C=2C3=CC=CC=C3C=CC=2PC=2C=CC=CC=2)C=1PC1=CC=CC=C1 GFNAXQJAAAXIQF-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000000109 phenylethoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- HDMGAZBPFLDBCX-UHFFFAOYSA-M potassium;sulfooxy sulfate Chemical compound [K+].OS(=O)(=O)OOS([O-])(=O)=O HDMGAZBPFLDBCX-UHFFFAOYSA-M 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002400 serotonin 2A antagonist Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical group C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- QHMQWEPBXSHHLH-UHFFFAOYSA-N sulfur tetrafluoride Chemical compound FS(F)(F)F QHMQWEPBXSHHLH-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention belongs to the field of medicinal chemistry.
- the present invention relates to a heterocyclic compound represented by the formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition and a medicament for the preparation of a central nervous system disorder Application in medicine.
- Psychosis is mainly a group of neurological diseases mainly characterized by disorders in behavior and psychological activities.
- the clinical manifestations are abnormal mental activities, which are manifested as perception, thinking, attention, memory, emotion, behavior and will intelligence and consciousness. Aspects of varying degrees of barriers.
- the dopamine system regulates physiological processes such as exercise, emotion, reward, and cognition.
- 5-HT 5-HT
- 5-HT is also involved in the regulation of various physiological functions, such as thermoregulation, emotional activity, pain, and sleep-wake. Therefore, most of the existing drugs in the central nervous system are related to the regulation of central nervous system transmitters such as dopamine and 5-HT.
- D 2 antagonists are classic antipsychotics and are also used in the treatment of insomnia; 5-HT 2A receptor antagonism reduces EPS, improves negative symptoms, improves cognitive impairment, improves depressive symptoms, improves anxiety and improves insomnia Role (European Journal of Pharmacology, 2000, 407: 39-46). However, simple D 2 antagonists or D 2 antagonist/5-HT 2A antagonists still have varying degrees of side effects.
- 5-HT 1A receptor agonists have shown good clinical application prospects in the treatment of major depression, anxiety, depression, and improvement of negative symptoms and cognitive function in patients with schizophrenia (CNS Drugs, 2013 Sep, 27: 703- 16).
- the 5-HT 1A receptor agonist BAY-3702 has neuroprotective, anxiolytic and antidepressant effects in animal models (European Journal of Pharmacology, 1998, 357: 1-8); gepirone can be used to alleviate certain Primary depressive disease (US4771053), such as major depression, endogenous depression, and atypical depression; buprenorphone can treat various symptoms associated with attention deficit and hyperactivity disorder (ADHD), and D
- the combination of 2 receptor agonists and 5-HT 1A receptor agonists can effectively treat ADHD and Parkinson's disease (WO200016777A); ixabepilone can effectively treat Alzheimer's disease or Parkinson's disease by improving memory. Cognitive decline in the disease (US 5,824,680).
- Dopamine receptor partial agonists can improve positive symptoms of schizophrenia, negative symptoms, anxiety and depression, cognitive deficits, and rarely cause an increase in serum prolactin like D 2 antagonist, D 2 antagonist/5-HT 2A antagonism Adverse reactions such as weight gain and metabolic abnormalities caused by the agent are safe and well tolerated.
- drugs with DA/5-HT multi-target effect are beneficial for better regulating the balance of multiple receptors in the brain and regulating the DA/5-HT system to treat diseases in the central nervous system.
- the present invention provides a class of compounds having 5-HT 2A and/or D 2 receptor and/or 5-HT 1A multi-target action activity, which can be used for the treatment of central nervous system diseases, especially depression and bipolar disorder. , schizophrenia, anxiety, phobia, autism, Alzheimer's disease, bipolar disorder, snoring, obsessive-compulsive disorder, ADHD and other diseases.
- the object of the present invention is to provide a class of antagonistic effects against serotonin 2A (5-HT 2A ) receptors and/or good for dopamine D 2 receptors and/or serotonin 1A (5-HT 1A ) receptors. Active compound.
- An object of the present invention is to provide a heterocyclic compound represented by the formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
- Another object of the invention is to provide a process for the preparation of the compounds of the invention.
- Still another object of the present invention is to provide a use of the heterocyclic compound represented by the general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for preventing and/or treating a central nervous system disease.
- a further object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (I) according to the present invention, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
- A, B and D are each independently C or N, and when A is N, D is also N;
- E is CH, N or C; when E is CH or N, it is connected to E Represents a single key; when E is C, it is connected to E Represents a double bond;
- a carbamoyl group (-CONH 2 ), a carbamoyl group substituted by a C1
- R 2 is absent, or 1 to 3 are each independently selected from the group consisting of halogen, hydroxy, decyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkyl , halogenated C1-C6 alkyl, nitro, amino, amino substituted by C1-C6 alkyl, cyano, carboxyl, aldehyde, amino C1-C6 alkyl, hydroxy C1-C6 alkyl, cyano C1 ⁇ C6 alkyl group, C1-C6 alkanoyl group, halogenated C1-C6 alkanoyl group, sulfonic acid group (-SO 2 OH), sulfonylamino group (-SO 2 NH 2 ), carbamoyl group (-CONH 2 ), C1 -C6 alkyl-substituted carbamoyl group, carboxy C1-
- R 3 is hydrogen or 1 to 4 substituents each independently selected from a hydroxyl group or a C1 to C6 alkyl group; preferably hydrogen or 1 to 4 substituents each independently selected from a hydroxyl group or a C1 to C4 alkyl group; Preferred is hydrogen or from 1 to 4 substituents each independently selected from hydroxy, methyl or ethyl;
- the G ring is a monocyclic heterocyclic group or a bicyclic heterocyclic group
- the bicyclic heterocyclic group is a benzomonocyclic heterocyclic group, a cycloalkyl-heterocyclic heterocyclic group or a monocyclic heterocyclic-monocyclic heterocyclic group.
- the monocyclic heterocyclic group contains at least one hetero atom selected from N, S and O; preferably a 3- to 10-membered monocyclic heterocyclic group, a benzo[3- to 10-membered monocyclic heterocyclic group], [C3 -C10 cycloalkyl]][3 to 10 membered monocyclic heterocyclic group] and [3 to 10 membered monocyclic heterocyclic group] [3 to 10 membered monocyclic heterocyclic group]; more preferably 5 to 7 membered single Cycloheterocyclyl, benzo[5-7-membered monocyclic heterocyclyl], [C5-C7 cycloalkyl]-[5-7-membered monocyclic heterocyclyl] and [5-7-membered monocyclic heterocyclyl] And [5 to 7-membered monocyclic heterocyclic group]; more preferably furyl, dihydrofuranyl, tetrahydrofuranyl, thienyl, dihydrothien
- the G ring is connected to L by a carbon atom on the G ring and is connected to L;
- G ring is optionally substituted with one or more identical or different substituents
- the substituent on the G ring is halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, nitro, cyano, hydroxy, decyl Amino group, amino group substituted by C1-C6 alkyl group, azide group, C1-C6 alkanoyl group, halogenated C1-C6 alkanoyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, carboxy C1-C6 alkyl group a cyano C1-C6 alkyl group, a C2-C6 alkenyloxy group, a C2-C6 alkynyloxy group, a carbamoyl group (-CONH 2 ), a carbamoyl group substituted with a C1 to C6 alkyl group, a carboxyl group, and a hydroxyl group C1 to C6
- heterocyclic compound represented by the formula (I) of the present invention is selected from the following compounds:
- heterocyclic compound represented by the formula (I) of the present invention is selected from the compounds shown below:
- R 1 , R 2 , R 3 , L and G rings are as defined and preferred above.
- heterocyclic compounds represented by the formula (I) stereoisomers thereof or pharmaceutically acceptable salts thereof, the following compounds or pharmaceutically acceptable salts thereof are most preferred:
- the present invention provides a process for producing a heterocyclic compound represented by the general formula (I), which can be carried out by one of the following methods 1-5.
- Process 1 The compound of the formula (II) or a salt thereof is subjected to an N-alkylation reaction with a compound of the formula (III) or a salt thereof, as shown in the reaction formula 1:
- G ring, L, A, B, D, E, R 1 , R 2 and R 3 are as defined above and preferred;
- X represents a leaving group such as halogen, C1-C6 alkylsulfonyloxy, benzenesulfonyloxy, naphthalenesulfonyloxy, the above C1-C6 alkylsulfonyloxy, benzenesulfonyloxy, naphthalene
- the sulfonyloxy group may be optionally further substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, hydroxy, amino and C1-C6 alkanoyl;
- the N-alkylation reaction between the compound of the formula (II) or a salt thereof and the compound of the formula (III) or a salt thereof is carried out in the absence of a solvent, or in the presence or absence of a base In the solvent.
- the solvent includes water; ethers such as dioxane, tetrahydrofuran, diethyl ether, methyl tert-butyl ether, diisopropyl ether, diglyme, ethylene glycol dimethyl ether, etc.; aromatic hydrocarbons, Such as: benzene, toluene, xylene, nitrobenzene, chlorobenzene, etc.; alcohols, such as: methanol, ethanol, isopropanol, butanol, tert-butanol, ethylene glycol; ketones, such as acetone, methyl ethyl ketone, 4 -methyl-2-pentanone, etc.; amides such as N,N-d
- the base may be selected from an inorganic base or an organic base, and the inorganic base includes an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, barium hydroxide, lithium hydroxide; an alkali metal carbonate such as sodium carbonate, Potassium carbonate, cesium carbonate, lithium carbonate; alkali metal hydrogen carbonate, such as: sodium hydrogencarbonate, potassium hydrogencarbonate, lithium hydrogencarbonate; alkali metals, such as: potassium, sodium; others, such as: sodium amide, potassium amide, sodium hydride Potassium hydride; organic bases include sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium acetate, triethylamine, pyridine, diisopropylamine, diisopropylethylamine, tripropylamine, diethylamine, pyrimidine, Quinoline, piperidine, piperazine, imidazole, dimethylaminopyridine, trimethylamine
- the above reaction can be carried out by adding an alkali metal iodide such as potassium iodide and sodium iodide as a reaction accelerator.
- an alkali metal iodide such as potassium iodide and sodium iodide
- the above reaction is usually carried out at room temperature to 200 ° C, preferably at room temperature to 150 ° C, and the reaction is usually carried out in about 1 to 30 hours, preferably within 5 to 20 hours.
- Process 2 A compound represented by the formula (IV) or a salt thereof is subjected to a coupling reaction with a compound represented by the formula (V) or a salt thereof, as shown in the reaction formula 2:
- G ring, L, A, B, D, R 1 , R 2 and R 3 are as defined and preferred above, and E 1 represents a nitrogen atom;
- X 1 represents a halogen or a trifluoromethanesulfonyloxy group, preferably bromine, Iodine, chlorine or trifluoromethanesulfonyloxy;
- the coupling reaction is carried out in the presence of palladium catalysis and a base, and the obtained compound of the formula (Ia) is a specific example of the compound of the formula (I).
- the palladium catalyst is palladium acetate (Pd(OAc) 2 ), bis(triphenylphosphine)palladium dichloride ((Ph 3 P) 2 PdCl 2 ), bis(benzonitrile)palladium chloride ((PhCN)) 2 PdCl 2 ), tetrakis(triphenylphosphine)palladium (Pd(PPh 3 ) 4 ), bis(triphenylphosphine)palladium acetate ((Ph 3 P) 2 Pd(OAc) 2 ), 1,2-di (diphenylphosphino)ethane palladium dichloride ((PdCl 2 (dppe) 2 )), bis(1,2-bis(diphenylphosphino)ethane)palladium (Pd(dppe) 2 ), double (dibenzylideneacetone) palladium (Pd(dba) 2 ), tris(dibenzylideneacetone
- the reaction solvent is not particularly limited as long as it does not interfere with the reaction, including water; ethers such as dioxane, tetrahydrofuran, etc.; aromatic hydrocarbons such as toluene, xylene, etc.; alcohols such as: uncle Butanol or the like; ketones such as acetone; amides such as N,N-dimethylformamide; others such as dimethyl sulfoxide, acetonitrile, etc.; or a mixture of the above solvents; if necessary
- the above reaction can be carried out by adding a suitable ligand as a reaction accelerator.
- Suitable ligands are 2,2'-diphenylphosphino-1,1'-binaphthyl (BINAP), tri-tert-butyl (P(t-Bu) 3 ), 1,1'-di-(diphenyl) Phosphyl)ferrocene (dppf), 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl (x-phos), 4,5-bisdiphenylphosphine-9,9-di Xantphos, tri-tert-butylphosphine tetrafluoroborate and tris(2-methylphenyl)phosphine (P(o-tolyl) 3 ).
- BINAP 2,2'-diphenylphosphino-1,1'-binaphthyl
- P(t-Bu) 3 tri-tert-butyl
- dppf 1,1'-di-(diphenyl) Phosphyl
- Process 3 Amidation reaction of a compound of the formula (VI) or a salt thereof with a compound of the formula (III) or a salt thereof to obtain a formula (VII) A compound or a salt thereof; a compound of the formula (VII) or a salt thereof treated with a reducing agent to give a compound of the formula (I), as shown in the reaction formula 3:
- G ring, L, A, B, D, E, R 1 , R 2 and R 3 are as defined above and preferred.
- the amidation reaction can be carried out in two ways.
- the first amidation process is the first activation of the carboxyl group of the compound of formula (VI) with or without a catalyst followed by an aminolysis reaction with a compound of formula (III).
- the activator may be selected from the group consisting of thionyl chloride, oxalyl chloride, brominated sulfoxide, phosphorus oxychloride, phosphorus pentachloride, pivaloyl chloride, ethyl chloroformate, isobutyl chloroformate, carbonyl diimidazole.
- the catalyst may be one or more selected from the group consisting of N,N-dimethylformamide (DMF), diethylaniline, dimethylaniline, N-methylmorpholine and the like.
- DMF N,N-dimethylformamide
- the reaction solvent for activating the carboxyl group is not particularly limited as long as it does not interfere with the reaction, and may be, for example, selected from the group consisting of dichloromethane, dichloroethane, dimethyl sulfoxide, tetrahydrofuran, benzene, toluene, chloroform, carbon tetrachloride.
- the aminolysis reaction is carried out in the presence of a base in a suitable solvent.
- the base may be selected from the group consisting of pyridine, piperidine, pyrrolidine, morpholine, N-methylmorpholine, quinoline, 4-dimethylaminopyridine (DMAP), triethylamine, diethylamine, tri-n-butyl Amine, tripropylamine, diisopropylamine, diisopropylethylamine, sodium methoxide, sodium ethoxide, potassium t-butoxide, butyl lithium, 1,8-diaza heterocycle [5,4,0] Undecene-7 (DBU), N-methylmorpholine, quinoline, 4-dimethylaminopyridine (DMAP), sodium hydrogen, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium hydrogencarbonate, hydrogencarbonate One or more of potassium, sodium carbonate and potassium carbonate.
- DMAP dimethylaminopyridine
- the reaction solvent of the aminolysis reaction may be selected from the group consisting of an aromatic hydrocarbon solvent, an ether solvent, a halogenated hydrocarbon solvent, other solvents, and a combination thereof.
- the aromatic hydrocarbon solvent may be, for example, one or more selected from the group consisting of benzene, toluene, xylene, and the like; and the ether solvent may be, for example, selected from tetrahydrofuran (THF), diethyl ether, and methyl tert-butyl ether.
- the halogenated hydrocarbon solvent may be, for example, selected from dichloro One or more of methane, chloroform, carbon tetrachloride, dichloroethane, etc.; the other solvent may be, for example, selected from the group consisting of methanol, ethanol, ethylene glycol, n-hexane, cyclohexane, N, N- One or more of dimethylformamide (DMF), N,N-dimethylacetamide, dimethyl sulfoxide (DMSO), N-methylpyrrolidone, acetone, acetonitrile, ethyl acetate, etc., but The present invention is not limited to the above solvents.
- the reaction temperature of the aminolysis reaction is not particularly limited, but is preferably between -30 ° C and 150 ° C, more preferably between -10 ° C and 120 ° C.
- the reaction time of the aminolysis reaction is not particularly limited, but is preferably between 10 minutes and 24 hours.
- the second amidation process is carried out using a condensing agent, with or without a catalyst, in the presence or absence of a base.
- the condensing agent may be selected from the group consisting of N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCl), N , N'-diisopropylcarbodiimide (DIC), O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), O-( 7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), benzotriazole-N,N,N',N'-four Methylurea hexafluorophosphate (HBTU), benzotriazol-1-yloxytris(di
- the catalyst may be one or more selected from the group consisting of 1-hydroxy-benzotriazole (HOBt), 4-dimethylaminopyridine (DMAP) and the like.
- the base may be selected from the group consisting of triethylamine, diethylamine, tri-n-butylamine, tripropylamine, diisopropylamine, diisopropylethylamine, trimethylamine, pyridine, 2,6-dimethyl Pyridine, 4-dimethylaminopyridine, piperidine, pyrrolidine, quinoline, morpholine, N-methylmorpholine, N-ethylmorpholine, diisopropylamine, diisopropylethylamine, 1, One of 8-diazahetero[5,4,0]undecene-7 (DBU) or 1,5-diazabicyclo[4.3.0]-indol-5-ene (DBN) Or several.
- DBU 8-diazahetero
- the reaction solvent of the second amidation method may be selected from the group consisting of hydrocarbons such as benzene, xylene, toluene, dichloromethane or chloroform; ethers such as tetrahydrofuran, diethyl ether, propyl ether or 1,4-dioxane.
- hydrocarbons such as benzene, xylene, toluene, dichloromethane or chloroform
- ethers such as tetrahydrofuran, diethyl ether, propyl ether or 1,4-dioxane.
- the reaction temperature of the second amidation method is not particularly limited as long as it does not affect the progress of the reaction, but is preferably between -20 ° C and 80 ° C, more preferably between 0 ° C and 50 ° C.
- the reducing agent is borane, hydrogen/palladium carbon, lithium tetrahydrogen aluminum, sodium triacetoxyborohydride, diisobutylaluminum hydride, boron trifluoride, boron tribromide, sodium borohydride and potassium borohydride. One or several of them.
- G ring, L, A, B, D, E, R 1 , R 2 and R 3 are as defined above and preferred.
- the reductive amination reaction is carried out in the presence of a reducing agent including, but not limited to, sodium borohydride, potassium borohydride, sodium triacetoxyborohydride (NaBH(OAc) 3 ), tetramethyltriacetyl Ammonium borohydride, sodium cyanoborohydride, and the like.
- a reducing agent including, but not limited to, sodium borohydride, potassium borohydride, sodium triacetoxyborohydride (NaBH(OAc) 3 ), tetramethyltriacetyl Ammonium borohydride, sodium cyanoborohydride, and the like.
- the reaction solvent is selected from the group consisting of waters; ethers such as dioxane, tetrahydrofuran, diethyl ether, methyl tert-butyl ether, Diisopropyl ether, diglyme, ethylene glycol dimethyl ether, etc.; aromatic hydrocarbons, such as: benzene, toluene, xylene, nitrobenzene, chlorobenzene, etc.; alcohols, such as: methanol, ethanol, Isopropanol, butanol, tert-butanol, ethylene glycol; ketones such as acetone, methyl ethyl ketone, 4-methyl-2-pentanone, etc.; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, etc.; halogenated hydrocarbons, such as: chloroform, dichloromethane, dichloroethane,
- the compound of the formula (I) obtained by the methods 1 to 4 is subjected to functional group conversion, such as by an oxidation reaction, a Grignard reaction, a hydrolysis reaction, a fluorination reaction, a chlorination reaction or a thio reaction.
- functional group conversion such as by an oxidation reaction, a Grignard reaction, a hydrolysis reaction, a fluorination reaction, a chlorination reaction or a thio reaction.
- the oxidation reaction is carried out in the presence of an oxidizing agent including, but not limited to, Dess-Martin oxidant, Jones reagent, Swern reagent (DMSO and oxalyl chloride), and 2,3-dichloro-5,6-dicyanide pair. Benzoquinone (DDQ), etc.
- an oxidizing agent including, but not limited to, Dess-Martin oxidant, Jones reagent, Swern reagent (DMSO and oxalyl chloride), and 2,3-dichloro-5,6-dicyanide pair.
- DDQ Benzoquinone
- the Grignard reaction is carried out in the presence of a Grignard reagent including, but not limited to, methyl magnesium chloride, methyl magnesium bromide, methyl magnesium iodide, and ethyl magnesium bromide.
- a Grignard reagent including, but not limited to, methyl magnesium chloride, methyl magnesium bromide, methyl magnesium iodide, and ethyl magnesium bromide.
- the hydrolysis reaction can be carried out in the presence of an acid or a base including, but not limited to, hydrochloric acid, sulfuric acid, sodium hydroxide, potassium hydroxide, and the like.
- the fluorination reaction is carried out in the presence of a fluorinating agent including, but not limited to, diethylaminosulfur trifluoride (DAST), sulfur tetrafluoride, and iodine pentafluoride.
- a fluorinating agent including, but not limited to, diethylaminosulfur trifluoride (DAST), sulfur tetrafluoride, and iodine pentafluoride.
- the chlorination reaction is carried out in the presence of a chlorinating agent including, but not limited to, thionyl chloride, phosphorus pentachloride, and N-chlorosuccinimide (NCS).
- a chlorinating agent including, but not limited to, thionyl chloride, phosphorus pentachloride, and N-chlorosuccinimide (NCS).
- the thiolation reaction is carried out in the presence of a thiol reagent including, but not limited to, phosphorus pentasulfide and Lawson's reagent, and the like.
- a thiol reagent including, but not limited to, phosphorus pentasulfide and Lawson's reagent, and the like.
- the compound of formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VIII) is a commercially available compound or is prepared according to methods known in the art or similar Preparation of a synthetic method of the compound.
- the starting compound used in each of the above reaction formulas may be a suitable salt
- the suitable salts include alkali metal salts and alkaline earth metal salts such as sodium salts, potassium salts, calcium salts, magnesium salts and the like; and organic base salts such as pyridinium salts.
- inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, etc.
- organic acid salts such as formate, acetate, propionate , glycolate, oxalate, malonate, succinate, fumarate, maleate, lactate, malate, citrate, tartrate, picrate, Glutamate, methanesulfonate and besylate;
- the starting compounds used in the above respective reaction formulas may include a solvate form such as a hydrate, an alcoholate or the like.
- heterocyclic compound represented by the formula (I) of the present invention and stereoisomers thereof also include solvate forms thereof such as hydrates, alcoholates and the like, and the solvates are included in the scope of the present invention. Inside.
- heterocyclic compound represented by the formula (I) of the present invention and a pharmaceutically acceptable salt thereof as the stereoisomer thereof mean that the heterocyclic compound represented by the formula (I) or a stereoisomer thereof is treated with a suitable acid They are converted into therapeutically active non-toxic addition salt forms.
- the salt such as hydrochloride, hydrobromide, hydroiodide, sulfate or hydrogen sulfate, nitrate, phosphate or acid phosphate, perchlorate, formate, acetate, Trifluoroacetate, propionate, pyruvate, glycolate, oxalate, malonate, succinate, glutarate, maleate, fumarate, milk Acid salt, malate, citrate, tartrate, picrate, glutamate, benzoate, methanesulfonate, ethanesulfonate, besylate, p-toluenesulfonate, water Salicylate, ascorbate, camphorate or camphor sulfonate.
- solvates are included in the scope of the present invention.
- examples of the solvate are, for example, hydrates, alcoholates and the like.
- Each of the target compounds obtained from the respective reaction formulas can be isolated and purified from the reaction mixture by, for example, the reaction mixture is subjected to cooling, followed by filtration, extraction or concentration to separate the crude product, followed by a conventional column. Purification is carried out by chromatography, beating or recrystallization.
- the present invention also provides the use of the heterocyclic compound of the formula (I) according to the present invention, a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for preventing and/or treating a central nervous system disease.
- the present invention also provides a method for treating and/or preventing a central nervous system disease, which comprises administering to a human or an animal a heterocyclic compound represented by the above formula (I) of the present invention, a stereoisomer thereof or A pharmaceutically acceptable salt thereof.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of the heterocyclic compound represented by the above formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier .
- the pharmaceutical composition can be used to treat or prevent diseases of the central nervous system.
- the present invention also provides a process for preparing a pharmaceutical composition
- a process for preparing a pharmaceutical composition comprising mixing a heterocyclic compound represented by the above formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.
- a plurality of pharmaceutical preparation forms can be selected according to the purpose of treatment, and generally include: tablets, pills, capsules, granules, suspensions, solutions, creams, ointments, powders, suppositories, and qi. Inhalation, injections, etc.
- the above central nervous system diseases are selected from: schizophrenia; difficult to control, refractory or chronic schizophrenia; emotional disorders; mental disorders; emotional disorders; type I bipolar affective disorder; type II bipolar affective disorder; Intrinsic depression; major depression; uncontrollable depression; emotional disorders; circulatory affective disorder; panic attacks; panic disorder; social phobia; obsessive-compulsive and behavioral disorders; impulsive disorders; Post-stress disorder; anxiety disorder; acute stress disorder; rickets; anorexia nervosa; sleep disorders; adaptive disorders; cognitive impairment; autism; neuropathic headache; mania; Parkinson's disease; Huntington's disease Alzheimer's disease; various dementias; memory disorders; ADHD; attention deficit/hyperthyroidism and tic disorder.
- halogen generally means fluorine, chlorine, bromine and iodine; preferably fluorine, chlorine or bromine; more preferably fluorine or chlorine;
- the C1-C6 alkyl group means a straight or branched saturated hydrocarbon group having 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl. , sec-butyl, n-pentyl, 1-ethylpropyl, isopentyl, neopentyl, isohexyl, 3-methylpentyl or n-hexyl, etc., preferably methyl, ethyl, n-propyl, Isopropyl, butyl, isobutyl or tert-butyl;
- the halogenated C1-C6 alkyl group means that a hydrogen atom of a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms is substituted by one or more halogen atoms which may be the same or different, for example, a trifluoromethyl group or a fluorine group.
- Base difluoromethyl, chloromethyl, bromomethyl, dichlorofluoromethyl, chloroethyl, bromopropyl, 2-chlorobutyl or pentafluoroethyl;
- C1-C6 alkoxy refers to a straight or branched alkoxy group having 1 to 6 carbon atoms, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso Butoxy, tert-butoxy, sec-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, isohexyloxy, 3-methylpentyloxy or n-hexyloxy, etc., preferably methoxy Base, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy;
- Halogenated C1-C6 alkoxy means that a hydrogen atom of a straight or branched alkoxy group having 1 to 6 carbon atoms is substituted by one or more of the same or different halogen atoms, for example, -OCF 3 , -OCH 2 CH 2 Cl, -OCHBrCH 2 Cl or -OCF 2 CF 3 ;
- the C1-C6 alkylthio group means a straight-chain or branched alkylthio group having 1 to 6 carbon atoms, for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, and iso Butylthio, tert-butylthio, sec-butylthio, n-pentylthio, isopentylthio, neopentylthio or n-hexylthio, etc., preferably methylthio, ethylthio, n-propylthio, iso Propylthio, n-butylthio, isobutylthio or tert-butylthio;
- the C2-C6 alkenyl group means a linear or branched unsaturated hydrocarbon group having 1 to 3 double bonds and 2 to 6 carbon atoms, and includes both a cis configuration and a trans configuration, for example, a vinyl group, 1-propenyl, 2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 1-butenyl, 2-butene , 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1,3-butadienyl, 1,3-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 3,3-dimethyl-1-propenyl or 2-ethyl-1- Propylene or the like;
- C2-C6 alkynyl refers to a straight or branched alkynyl group having 2 to 6 carbon atoms, for example, ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl- 2-propynyl, 2-pentynyl, 2-pentynyl or 2-hexynyl;
- the phenyl C1-C6 alkyl group means that one carbon atom of a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms is bonded to a carbon atom of a phenyl group such as a benzyl group, a phenethyl group or a phenylpropyl group. ;
- Phenyl C1-C6 alkoxy means that one carbon atom of a straight or branched alkoxy group having 1 to 6 carbon atoms is bonded to a carbon atom of a phenyl group such as a benzyloxy group, -OCH(CH 3 )Ph , phenylethoxy or phenylpropoxy, etc.;
- phenyl C1 - C6 alkanoyl means that one carbon atom of a straight or branched alkanoyl group having 1 to 6 carbon atoms is bonded to a carbon atom of a phenyl group, such as benzene Formyl, phenylacetyl or phenylpropionyl;
- the C2-C6 alkenyloxy group means a linear or branched alkenyloxy group having 1 to 3 double bonds and 2 to 6 carbon atoms, such as B. Alkenyloxy, 1-propenyloxy, 1-methyl-1-propenyloxy, 2-methyl-1-propenyloxy, 1-pentenyloxy, 1,3-pentadienyloxy or 2 -pentenyloxy group;
- C2-C6 alkynyloxy means a straight-chain or branched alkynyloxy group having 2 to 6 carbon atoms, for example, ethynyloxy, 2-propynyloxy, 2-butynyloxy, 3-butynyloxy , 1-methyl-2-propynyloxy, 2-pentynyloxy or 2-hexynyloxy;
- the C1-C6 alkanoyl group means a straight or branched alkanoyl group having 1 to 6 carbon atoms, such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, t-butyryl or hexanoyl;
- halogenated C1 to C6 alkanoyl group means that a hydrogen atom in a straight or branched alkanoyl group having 1 to 6 carbon atoms is substituted by one or more halogen atoms which may be the same or different, for example, a trifluoroacetyl group;
- a carbamoyl group substituted by a C1-C6 alkyl group means that the hydrogen atom on the carbamoyl group is substituted by one or two C1 to C6 alkyl groups which may be the same or different, for example, -CONHMe, -CONHEt, -CON(Me)Et , -CONEt 2 or -CONMe 2, etc.;
- the hydroxy C1-C6 alkyl group means that one carbon atom of a linear or branched alkyl group having 1 to 6 carbon atoms is bonded to a hydroxyl group such as -CH 2 OH, -CH 2 CH 2 OH, -CH(OH)CH 3 , -CH 2 CH 2 CH 2 OH, -CH 2 CH 2 CH 2 CH 2 OH or -CH 2 CH(CH 3 )CH 2 OH;
- Amino C1-C6 alkyl refers to a carbon atom bonded to an amino group of a straight or branched alkyl group having 1 to 6 carbon atoms, such as -CH 2 NH 2 , -CH 2 CH 2 NH 2 , -CH(NH 2 ) CH 3 , -CH 2 CH 2 CH 2 NH 2 or -CH 2 CH 2 CH 2 CH 2 NH 2 , etc.; an amino C1-C6 alkyl group substituted by a C1-C6 alkyl group means that a hydrogen atom on the amino group is 1 or 2 identical or different C1-C6 alkyl groups, such as -CH 2 NHMe or -CH 2 CH 2 NEt 2 ;
- the carbamoyl C1-C6 alkyl group means that one carbon atom of a linear or branched alkyl group having 1 to 6 carbon atoms is bonded to a carbonyl carbon of a carbamoyl group, for example, -CH 2 CONH 2 , -CH 2 CH 2 CONH 2 , -CH(CONH 2 )CH 3 or -CH 2 CH 2 CH 2 CONH 2 ;
- the carbamoyl C1 to C6 alkyl group substituted by a C1 to C6 alkyl group means that the amino hydrogen atom on the C1 to C6 alkyl group of the carbamoyl group is substituted by one or two C1 to C6 alkyl groups which are the same or different, for example, CH 2 CONHMe, -CH 2 CH 2 CONHEt, -CH 2 CH 2 CONMe 2 -CH 2 CONEt 2, or the like;
- the cyano C1-C6 alkyl group means that one carbon atom of a linear or branched alkyl group having 1 to 6 carbon atoms is bonded to a cyano group such as a cyanomethyl group, a 2-cyanoethyl group or a 1-cyano group. Ethyl, 3-cyanopropyl, 4-cyanobutyl or 5-cyanopentyl;
- the carboxy C1-C6 alkyl group means a carbon atom bonded to a carboxyl group with a straight or branched alkyl group having 1 to 6 carbon atoms, such as a carboxymethyl group, a 2-carboxyethyl group, a 1-carboxyethyl group, or a 3- Carboxypropyl, 4-carboxybutyl or 5-carboxypentyl, etc.;
- a C1-C6 alkanesulfonyl group means a straight-chain or branched alkylsulfonyl group having 1 to 6 carbon atoms, such as a methylsulfonyl group, an ethylsulfonyl group or a propylsulfonyl group;
- the halogenated C1 to C6 alkylsulfonyl group means that a hydrogen atom on a linear or branched alkanesulfonyl group having 1 to 6 carbon atoms is substituted by one or more halogen atoms which may be the same or different, for example, a trifluoromethanesulfonyl group. Wait;
- the amino group substituted by a C1 to C6 alkyl group means that the hydrogen atom on the amino group is substituted by one or two C1 to C6 alkyl groups or C1 to C6 alkanoyl groups which are the same or different, for example, -NHMe or -NEt 2 ;
- the C3-C10 cycloalkyl group means a saturated or unsaturated cyclic hydrocarbon group having 3 to 10 carbon atoms, such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclobutene group. , cyclohexene, cyclohexadiene, cyclopentene or cyclopentadiene;
- the 3-10 membered monocyclic heterocyclic group means a monocyclic group containing at least one hetero atom selected from N, S and O, such as ethylene oxide, azetidinyl, furyl, dihydrofuranyl, tetrahydrofuran.
- the compounds of the invention have good activity against the serotonin 1A (5-HT 1A ) receptor and/or the dopamine D 2 receptor and/or the serotonin 2A (5-HT 2A ) receptor; especially for 5- The HT 1A receptor has high activity, and the EC 50 of some compounds for 5-HT 1A receptor agonism even reaches the level of 1 to 0.1 nM.
- the compound of the present invention has multi-target action characteristics and acts on multiple subtypes of dopamine/5-hydroxytryptamine receptor, i.e., simultaneously to dopamine D 2 receptor, 5-HT 1A receptor, 5-HT 2A At least three targets such as receptors have high activity; as shown by pharmacological experiments, most of the compounds have D 2 antagonist/5-HT 1A agonistic/5-HT 2A antagonism, or have D 2 partial agonism/5-HT.
- the compound of the present invention is a central nervous system receptor modulator, thereby reducing or avoiding side effects caused by a single D 2 antagonist or D 2 antagonist/5-HT 2A antagonist, for example, Extrapyramidal adverse reactions (EPS), side effects of metabolic disorders, etc.
- EPS Extrapyramidal adverse reactions
- the compound of the present invention is not only active, but also effective orally, has low pharmacological dose, small toxic and side effects, and has curative effect on diseases in the central nervous system, especially for major depression (MDD), anxiety, and schizophrenia. Negative symptoms, cognitive dysfunction, Parkinson's disease, ADHD and other diseases are effective.
- the compound of the present invention has the advantages of multiple target effects, lower pharmacodynamic dose, less toxic side effects, better safety and tolerance than the existing antipsychotic drugs, and has good clinical application. prospect.
- step 1
- step 1
- step 1
- the compound 6-c (1.5 g, 7.85 mmol) was dissolved in dichloromethane (60 ml), triethylamine (3 ml, 23.55 mmol) was added with stirring, and methanesulfonyl chloride (0.92 ml, 11.77 mmol) was added dropwise under ice bath. After the addition was completed, the reaction was carried out to room temperature for 3 hours. An appropriate amount of water was added, and the mixture was extracted with dichloromethane.
- step 1
- step 1
- the compound 1-e (900 mg, 2.83 mmol) was placed in a dry three-necked flask, dissolved in tetrahydrofuran (3 ml) under nitrogen atmosphere, cooled to -78 ° C, and poured into a solution of 2.5 M n-butyllithium in n-hexane (1.47 ml). , 3.67mmol), maintain -78 ° C anti It should be 3 hours.
- N-chlorosuccinimide (677 mg, 5.09 mmol) was dissolved in tetrahydrofuran (3 ml), and slowly poured into the reaction system. After half an hour, the mixture was stirred at room temperature overnight, and the reaction was quenched by adding a saturated ammonium chloride solution. The mixture was extracted with EtOAc (EtOAc m.
- step 1
- step 1
- step 1
- Lithium tetrahydroaluminum (4.6 g, 121 mmol) was added to a flask containing dry tetrahydrofuran (20 ml), and a solution of compound 12-a (10 g, 53.2 mmol) in tetrahydrofuran (100 ml) was added dropwise in an ice bath.
- the mixture was stirred at room temperature for 20 minutes, and then heated to reflux. After 3 hours, the reaction was stopped, and sodium sulfate decahydrate was slowly added until the bubbles were no longer discharged, and the filtrate was filtered, dried, and then subjected to column chromatography.
- the product 12-b (7.8 g, yield: 85%) was obtained.
- step 1
- Methyl 2-aminothiophene-3-carboxylate (2.0 g, 12.7 mmol) was dissolved in formamide (60 ml), stirred and heated to 190 ° C for 4 hours. After cooling, it was poured into water (200 ml), and extracted with n-butanol (50 ml ⁇ 4). After concentration, the residue was subjected to EtOAc mjjjjjj ESI-MS (m/z): 153.0 [M+H] + .
- 1 H-NMR 300 Hz, DMSO-d 6 ): ⁇ ppm 7.39 (d, 1H), 7.57 (d, 1H), 8.12 (s, 1H), 12.49 (brs, 1H).
- the compound 13-d (900 mg) was dissolved in dichloromethane (10 ml), cooled to 0 ° C, and trifluoroacetic acid (1 ml) was added. The reaction mixture was concentrated to dryness EtOAc.
- step 1
- N-N-dimethylformamide (250 ml) and potassium carbonate (51.5 g, 373 mmol) were added to a three-necked flask, and protected with N 2 , and ethyl acetate (13.7 ml) was added dropwise at room temperature.
- 14-b (25.2g, 124mmol)
- the reaction was completed overnight
- the reaction was completed
- filtered the filtrate was washed once with water, then washed once with saturated sodium chloride solution, dried
- the organic phase was concentrated to give a crude material. m.j.
- step 1
- step 1
- step 1
- the benzothiazole-2(3H)-one 20-a (500 mg, 3.307 mmol) was suspended in carbon disulfide (8 ml), and anhydrous aluminum chloride (2.65 g, 19.841 mmol) was added portionwise in an ice bath, and then slowly dripped. Chloroacetyl chloride (324 ul, 4.299 mmol) was added and allowed to stir at room temperature for 10 minutes and then refluxed for 1.5 hours. The reaction mixture was quenched with a small amount of ice water, and the mixture was evaporated to dryness, and the mixture was evaporated. The mixture was evaporated. The mixture was evaporated. Two times, the filter cake was dried to give a pink solid 20-b (740 mg, yield: 98%).
- step 1
- 2H-1,4-benzoxazine-3(4H)-one 21-a (500 mg, 3.356 mmol) was suspended in dichloromethane (8 ml), and anhydrous aluminum chloride (895 mg, 6.712mmol), slowly add dropwise chloroacetyl chloride (330ul, 4.363mmol), add it to the mixture at room temperature for 10 minutes, reflux for 5 hours, add a small amount of ice water to the reaction solution to quench the reaction, concentrate to remove dichloromethane , the residue was added with ice water (10 ml), 4N hydrochloric acid (5 ml) was added, and the mixture was stirred at room temperature for 2 hours, filtered, and the filter cake was washed twice with ice water to give a pale yellow solid 21-b (690 mg, yield: 91%) ).
- step 1
- step 1
- Triethylamine (125 ul, 0.87 mmol) was added to a solution of compound 23-a (100 mg, 0.43 mmol) in dichloromethane (5 ml), and methanesulfonyl chloride (51 ul, 0.65 mmol) was added to the above reaction system under ice bath. The reaction was allowed to stand at room temperature for 2 hours, and the reaction mixture was diluted with methylene chloride, washed with saturated aqueous ammonium chloride, and the organic layer was dried, and evaporated to give a white solid (71 mg, yield: 53%).
- ESI-MS (m/z): 311.1 [M+H] + .
- Ethyl anthranilate 24-a (1.0 g, 6.62 mmol), acrylonitrile (0.88 ml, 13.24 mmol) was dissolved in dioxane, and hydrogen chloride / dioxane (10 ml) was slowly added in an ice bath. Stir for 4 hours, heat the tube to 80 ° C overnight, then evaporate the solvent, add water, dichloromethane, adjust the pH to 7-8 with ammonia water, filter, solid dry, beat with methyl tert-butyl ether, filter Dry to pale yellow solid (660 mg, yield: 52%).
- ESI-MS (m/z): 209.1 [M+H] + .
- step 1
- Triethylsilane (900 ul, 5.58 mmol) was added dropwise to a solution of compound 25-a (500 mg, 2.32 mmol) in trifluoroacetic acid and allowed to react at 30 ° C overnight.
- the reaction solution was poured into ice water, extracted with dichloromethane three times, the organic phase was combined, dried, concentrated, and beaten in a mixture of petroleum ether: acetone (30:1, volume ratio), filtered, and the filter cake was dried. Pale pink solid (430 mg, yield: 92%).
- step 1
- the diisopropylamine (2.4 g, 24.0 mmol) was dissolved in anhydrous tetrahydrofuran (20 ml), and the mixture was stirred under nitrogen, and a n-hexane solution of n-butyllithium (9.6 ml, 24.0 mm) was added dropwise at 0 ° C. After reacting for 30 minutes, anhydrous tetrahydrofuran (30 ml) was added, and the mixture was cooled to -78 ° C, and a solution of 3,5-dibromopyridine 26-a (4.7 g, 20 mm) in anhydrous tetrahydrofuran (50 ml) was added dropwise.
- step 1
- step 1
- Chloroacetyl chloride (470 ul, 6.20 mmol) was added dropwise to an anhydrous aluminum chloride (2.48 g, 18.60 mmol) in a carbon disulfide suspension under ice bath, stirred for 10 minutes, and 4,5-dihydro-1H-benzene was added.
- Azazao-2(3H)-one 29-a 500 mg, 3.10 mmol
- Triethylsilane (840 uL, 5.25 mmol) was added dropwise to a solution of compound 29-b (500 mg, 2.10 mmol) in trifluoroacetic acid (5 ml).
- the reaction solution was poured into ice water, extracted with dichloromethane three times, and the organic phase was combined, dried, concentrated, and the residue was pulverized in isopropyl ether, filtered, and dried to give a pale yellow solid (430 mg, yield: 91.4% ).
- step 1
- step 1
- Diisopropylamine (5.14g, 50.8mmol) was dissolved in anhydrous tetrahydrofuran (50ml), protected with nitrogen, stirred, and n-hexane solution of n-butyllithium (20.3ml, 50.8mml) was added dropwise at 0 °C.
- the reaction solution was cooled to -78 ° C for 30 minutes, and a solution of 3-bromofluorobenzene 31-a (10.0 g, 42.4 mm) in anhydrous tetrahydrofuran (100 ml) was added dropwise, and the reaction was continued for 30 minutes after the dropwise addition, and methyl formate was added dropwise.
- the compound 31-f (3.24 g, 8.3 mmol) was dissolved in tetrahydrofuran (60 ml), and lithium hydroxide monohydrate (698 mg, 16.6 mmol) and methanol (10 ml) were added thereto with stirring, and reacted at room temperature for 5 hours, and added to the reaction mixture.
- the pH was adjusted to 4 to 5 with 1N hydrochloric acid, and the solid was separated, filtered, and the filter cake was dried in vacuo to give a white solid 31-g (2.8 g, yield: 96.5%).
- the product of Preparation 16 was obtained as 2-(6-chloro-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl methanesulfonate (330 mg, 1.09 mmol). Hexacyclic (5 ml) and 2,3-dichloro-5,6-dicyanyl p-benzoquinone (DDQ, 740 mg, 3.26 mmol) were heated to reflux overnight.
- DDQ 2,3-dichloro-5,6-dicyanyl p-benzoquinone
- step 1
- Chloroacetyl chloride (460 uL, 6.16 mmol) was added dropwise to a suspension of anhydrous aluminum chloride (1.03 g, 7.7 mmol) in 1,2-dichloroethane under ice bath, stirred for 10 minutes, and 3-methyl was added.
- Triethylsilane (587 ul, 3.68 mmol) was added dropwise to a solution of compound 33-b (350 mg, 1.47 mmol) in trifluoroacetic acid (4 ml), and reacted at 35 ° C for 2.5 hours, and the reaction mixture was poured into ice water to precipitate. Solid, filtered, filter cake washed with ice water 3 The mixture was dried to give a pale yellow solid (320 mg, yield: 97%).
- step 1
- Chloroacetyl chloride (640 ul, 8.49 mmol) was added dropwise to a suspension of anhydrous aluminum chloride (2.72 g, 20.38 mmol) in carbon disulfide (10 ml) under ice bath, stirred for 10 minutes, and 3,4-dihydroquinoline was added.
- Triethylsilane (900 uL, 5.58 mmol) was added dropwise to a solution of compound 35-b (500 mg, 2.32 mmol) in trifluoroacetic acid (5 ml) and allowed to react at 30 ° C overnight.
- the reaction solution was poured into ice water, extracted with dichloromethane (15 ml ⁇ 3), the organic phase was combined, dried, filtered, dried, concentrated, concentrated, and the residue was added with petroleum ether, filtered, and the filter cake was dried to give a tan solid. (417 mg, yield: 89%).
- step 1
- the object was prepared by the procedure of Preparation 37, using ethyl propiolate instead of ethyl 2-ethyl-3-oxopentanoate.
- Example 5 The product of Example 5 (120 mg, 0.28 mmol) was dissolved in dry tetrahydrofuran (3 ml), and methyl brunium bromide (2 ml, 1.99 mmol, 1 M in THF) was added dropwise to the above solution at room temperature under ice bath. After stirring for 3 hours, it is quenched by the addition of saturated ammonium chloride, and the residue is evaporated to dryness. It was beaten to a pale yellow solid (40 mg, yield: 32%).
- Example 17 The product of Example 17 (180 mg, 0.35 mmol) was. The reaction solution was cooled, and then added dropwise to isopropyl alcohol (5 ml), and solid was evaporated to give a pale yellow solid (130 mg, yield: 87%).
- Example 5 The product of Example 5 (120 mg, 0.28 mmol) was dissolved in dichloromethane (3 ml), and dichloromethane (3. It was added dropwise to the above solution and stirred at room temperature overnight. Add saturated sodium bicarbonate solution, extract with methylene chloride, wash the organic phase with saturated brine, dry over anhydrous sodium sulfate, and then remove the desiccant, concentrate, and the residue is obtained by column chromatography to give a crude salt in a hydrogen chloride-ethanol solution A pale yellow solid (50 mg, yield: 39%).
- Example 8 The product of Example 8 (500 mg, 1.325 mmol) was suspended in toluene (15 ml), and the solvent was added to the solvent (642 mg, 1.59 mmol), and the mixture was heated to 80 ° C overnight, and the reaction mixture was concentrated. The salt was formed in a hydrogen chloride-methanol solution, filtered, and the cake was then pulverized with a mixed solvent of isopropyl ether/methanol to give a yellow solid (40 mg, yield: 7.6%).
- the target product was prepared by following the procedure of Example 55 using the product of Preparation 38 and the product of Preparation 1.
- 1 H-NMR 300 Hz, DMSO-d 6 ): ⁇ ppm 9.45 (brs, 1H), 7.96 (d, 1H), 7.77 (d, 1H), 7.70 (d, 1H), 7.50 (d, 1H), 7.31 (t, 1H), 6.96 (d, 1H), 6.36 (d, 1H), 3.63 (t, 2H), 3.17-3.57 (m, 10H).
- ESI-MS (m/z): 341.0 [M+H ] + .
- Use LANCE TM cAMP 384 Kit (U.S. PerkinElmer Inc.) agonism compound tested expressing recombinant human 5-HT 1A receptors HEK293 cells 5-HT 1A receptor.
- the 5-HT 1A agonism of the compounds was assessed by testing the inhibitory effect of the compounds on cAMP production in HEK293 cells.
- the cAMP concentration test was carried out according to the method in the kit instructions. The test concentration of the compound was 0.1 nM-10000 nM, 8-OH-DPAT was used as a positive control, and the EC 50 was calculated by Excelfit software. The results are shown in Table 1.
- Use LANCE TM cAMP 384 Kit (U.S. PerkinElmer Inc.) antagonistic compounds tested recombinant D 2 receptors HEK293 cells expressing human D 2 receptor. Antagonism of dopamine inhibition by the test compound in HEK293 cells cAMP production to assess the compound D 2 antagonism.
- the cAMP concentration test was carried out according to the method in the kit instructions. The test concentration of the compound was 0.1 nM-10000 nM, risperidone was used as a positive control, and the IC 50 was calculated by Excelfit software. The results are shown in Table 1.
- Calcium 5 Assay Kit (Molecular Devices USA Inc.) antagonistic compounds tested recombinant 5-HT 2A receptor in CHO-K1 cells expressing human 5-HT 2A receptor.
- the test was carried out according to the method in the kit instructions, and the test concentration of the compound was 0.1 nM to 10000 nM, and risperidone was used as a positive control.
- the test method was as follows: On the first day, the seed cells were placed at a density of 14 million per bottle in a 25 ml growth medium (F-12 nutrient mixture + 10% FBS + 1% penicillin / streptomycin + 1.2% 50 mg / ml Geneticin).
- the cells were cultured for 24 hours at 37 ° C, 5% CO 2 , humidified; the next day, seed cells were seeded into 384-well cell culture plates, and each well was inoculated with 20,000 cells.
- 50 ⁇ L of the test medium F-12 nutrient mixture + 1.5% activated carbon-treated FBS
- the test medium was used to replace the growth medium, and the cells were cultured for 16 hours at 37 ° C, 5% CO 2 , humidified; the medium was removed on the third day.
- Use LANCE TM cAMP 384 Kit U.S. PerkinElmer Inc.
- D 2 agonism was assessed by compound inhibition of the test compound on the cAMP production in HEK293 cells.
- the cAMP concentration test was carried out according to the method in the kit instructions. The test concentration of the compound was 0.1 nM to 10000 nM, and dopamine was used as a positive control. The IC 50 was calculated by Excelfit software, and the results are shown in Table 2.
- PCP was dissolved in physiological saline to prepare a solution at a dose of 7 mg/kg.
- Aripiprazole and the test compound are formulated into a solution of a suitable concentration with a 0.5% CMC-Na solution, which is ready for use.
- the spontaneous sputum video analysis system was used to record the trajectory of the mice after 45 minutes of administration of the test drug or physiological saline, and then the trajectory of the mice within 75 minutes after administration of PCP was recorded.
- the activity trajectories of the mice were analyzed by a spontaneous and open-field video analysis system, and the total distance of activities of each group of mice was counted, and the results were expressed by mean ⁇ SD. Results were statistically analyzed using one-way analysis of variance.
- mice After PCP modeling, the spontaneous activity of the mice was significantly increased compared with the saline group.
- the test compound at the following doses (Table 3) significantly reduced the high spontaneous activity of PCP-induced mice, which was significantly different from the model group. .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (14)
- 一种由通式(I)表示的杂环化合物、其立体异构体或其药学上可接受的盐:其中:A、B和D各自独立地为C或N,且当A为N时,D同时也为N;R1为氢或1至4个各自独立地选自卤素、羟基、巯基、氧代(=O)、硫代(=S)、C1~C6烷氧基、卤代C1~C6烷氧基、C1~C6烷硫基、C1~C6烷基、卤代C1~C6烷基、硝基、氨基、被C1~C6烷基取代的氨基、氰基、羧基、醛基、氨基C1~C6烷基、羟基C1~C6烷基、氰基C1~C6烷基、C1~C6烷酰基、卤代C1~C6烷酰基、磺酸基(-SO2OH)、磺酰氨基(-SO2NH2)、氨基甲酰基(-CONH2)、被C1~C6烷基取代的氨基甲酰基、羧基C1~C6烷基、C1~C6烷磺酰基、卤代C1~C6烷磺酰基、被C1~C6烷基取代的氨基C1~C6烷基、氨基甲酰基C1~C6烷基或被C1~C6烷基取代的氨基甲酰基C1~C6烷基;R2不存在,或者为1至3个各自独立地选自卤素、羟基、巯基、C1~C6烷氧基、卤代C1~C6烷氧基、C1~C6烷硫基、C1~C6烷基、卤代C1~C6烷基、硝基、氨基、被C1~C6烷基取代的氨基、氰基、羧基、醛基、氨基C1~C6烷基、羟基C1~C6烷基、氰基C1~C6烷基、C1~C6烷酰基、卤代C1~C6烷酰基、磺酸基(-SO2OH)、磺酰氨基(-SO2NH2)、氨基甲酰基(-CONH2)、被C1~C6烷基取代的氨基甲酰基、羧基C1~C6烷基、C1~C6烷磺酰基、卤代C1~C6烷磺酰基、被C1~C6烷基取代的氨基C1~C6烷基、氨基甲酰基C1~C6烷基或被C1~C6烷基取代的氨基甲酰基C1~C6烷基;R3为氢或1至4个各自独立地选自羟基或C1~C6烷基的取代基;L不存在,或者为C1~C5亚烷基,且当L为C1~C5亚烷基时,该亚烷基非必须地被一个或多个选自羟基、C1~C6烷氧基和氧代基团(O=)中的取代基所取代;G环为单环杂环基或双环杂环基,所述双环杂环基为苯并单环杂环基、环烃基并单环杂环基或单环杂环基并单环杂环基,其中所述单环杂环基含有至少一个选自N、S和O的杂原子;G环与L的连接方式为通过G环上的碳原子与L相连;并且,G环非必须地被一个或多个相同或不同取代基取代;所述G环上的取代基为卤素、C1~C6烷基、卤代C1~C6烷基、C1~C6烷氧基、卤代C1~C6烷氧基、硝基、氰基、羟基、巯基、氨基、被C1~C6烷基取代的氨基、叠氮基、C1~C6烷酰基、卤代C1~C6烷酰基、C2~C6链烯基、C2~C6炔基、羧基C1~C6烷基、氰基C1~C6烷基、C2~C6链烯氧基、C2~C6炔氧基、氨基甲酰基(-CONH2)、被C1~C6烷基取代的氨基甲酰基、羧基、羟基C1~C6烷基、氧代(=O)、硫代(=S)、磺酰氨基(-SO2NH2)、C1~C6烷硫基、C1~C6烷磺酰基、卤代C1~C6烷磺酰基、磺酸基(-SO2OH)、醛基、氨基C1~C6烷基、被C1~C6烷基取代的氨基C1~C6烷基、氨基甲酰基C1~C6烷基、被C1~C6烷基取代的氨基甲酰基C1~C6烷基、C3-C10环烃基、C3-C10环烃基C1~C6烷基、C3-C10环烃基甲酰胺基、呋喃基、噻吩基、吡咯基、吡咯烷基、吡唑基、吡唑烷基、三唑基、三唑烷基、噻唑基、噻唑烷基、异噻唑基、异噻唑烷基、噁唑基、噁唑烷基、异噁唑基、异噁唑烷基、吡喃基、吡嗪基、哌嗪基、哒嗪基、吡啶基、哌啶基、嘧啶基、咪唑基、C3-C10环烃基C1~C6烷氧基、呋喃基C1~C6烷基、呋喃基C1~C6烷氧基、噻吩基C1~C6烷基、噻吩基C1~C6烷氧基、吡咯基C1~C6烷基、吡咯基C1~C6烷氧基、吡咯烷基C1~C6烷基、吡咯烷基C1~C6烷氧基、吡唑基C1~C6烷基、吡唑基C1~C6烷氧基、三唑基C1~C6烷基、三唑基C1~C6烷氧基、噻唑基C1~C6烷基、噻唑基C1~C6烷氧基、异噻唑基C1~C6烷基、异噻唑基C1~C6烷氧基、噁唑基C1~C6烷基、噁唑基C1~C6烷氧基、异噁唑基C1~C6烷基、异噁唑基C1~C6烷氧基、吡嗪基C1~C6烷基、吡嗪基C1~C6烷氧基、哒嗪基C1~C6烷基、哒嗪基C1~C6烷氧基、吡啶基C1~C6烷基、吡啶基C1~C6烷氧基、嘧啶基C1~C6烷基、嘧啶基C1~C6烷氧基、苯基、苯氧基、苯磺酰基、苯基C1~C6烷基、苯基C1~C6烷氧基、苯基C1~C6烷酰基或苯基C1~C6烷酰氧基;上述C3-C10环烃基、C3-C10环烃基C1~C6烷基、呋喃基、噻吩基、吡咯基、吡咯烷基、吡唑基、吡唑烷基、三唑基、三唑烷基、噻唑基、噻唑烷基、异噻唑基、异噻唑烷基、噁唑基、噁唑烷基、异噁唑基、异噁唑烷基、吡喃基、吡嗪基、哌嗪基、哒嗪基、吡啶基、哌啶基、嘧啶基、咪唑基、C3-C10环烃基C1~C6烷氧基、呋喃基C1~C6烷基、呋喃基C1~C6烷氧基、噻吩基C1~C6烷基、噻吩基C1~C6烷氧基、吡咯基C1~C6烷基、吡咯基C1~C6烷氧基、吡咯烷基C1~C6烷基、吡咯烷基C1~C6烷氧基、吡唑基C1~C6烷基、吡唑基C1~C6烷氧基、三唑基C1~C6烷基、三唑基C1~C6烷氧基、噻唑基C1~C6 烷基、噻唑基C1~C6烷氧基、异噻唑基C1~C6烷基、异噻唑基C1~C6烷氧基、噁唑基C1~C6烷基、噁唑基C1~C6烷氧基、异噁唑基C1~C6烷基、异噁唑基C1~C6烷氧基、吡嗪基C1~C6烷基、吡嗪基C1~C6烷氧基、哒嗪基C1~C6烷基、哒嗪基C1~C6烷氧基、吡啶基C1~C6烷基、吡啶基C1~C6烷氧基、嘧啶基C1~C6烷基、嘧啶基C1~C6烷氧基、苯基、苯氧基、苯磺酰基、苯基C1~C6烷基、苯基C1~C6烷氧基、苯基C1~C6烷酰基和苯基C1~C6烷酰氧基非必须地被一个或多个选自如下基团的取代基所取代:卤素、C1~C6烷基、卤代C1~C6烷基、C1~C6烷氧基、C1~C6烷氧酰基、卤代C1~C6烷氧基、硝基、氰基、羟基、氨基、C1~C6烷酰基、卤代C1~C6烷酰基、氨基甲酰基或羧基;条件是不包括以下化合物:1)1-[2-[4-(2-氰基-7-氟苯并噻吩-4-基)-2-甲基-1-哌嗪基]乙基]-3,4-二氢-1H-2-苯并吡喃-6-甲酰胺;2)1-[2-[4-(7-氟苯并噻吩-4-基)-2-甲基-1-哌嗪基]乙基]-3,4-二氢-1H-2-苯并吡喃-6-甲酰胺;3)6-乙基-4-[4-[2-(2-噻吩基)乙基]-1-哌嗪基]-噻吩并[2,3-d]嘧啶;4)6-[2-[4-(5-甲基噻吩并[2,3-d]嘧啶-4-基)-1-哌嗪基]乙基]-2H-1,4-苯并噁嗪-3(4H)-酮;5)6-乙基-4-[4-[3-[3-(2-噻吩基)-1,2,4-噁二唑-5-基]丙基]-1-哌嗪基]-噻吩并[2,3-d]嘧啶;6)5,6-二甲基-4-[4-[3-[3-(4-甲基苯基)-1,2,4-噁二唑-5-基]丙基]-1-哌嗪基]-噻吩并[2,3-d]嘧啶。
- 根据权利要求1所述的杂环化合物、其立体异构体或其药学上可接受的盐,其中,G环为3~10元单环杂环基、苯并[3~10元单环杂环基]、[C3-C10环烃基]并[3~10元单环杂环基]和[3~10元单环杂环基]并[3~10元单环杂环基]。
- 根据权利要求2所述的杂环化合物、其立体异构体或其药学上可接受的盐,其中,G环为5~7元单环杂环基、苯并[5~7元单环杂环基]、[C5-C7环烃基]并[5~7元单环杂环基]和[5~7元单环杂环基]并[5~7元单环杂环基]。
- 根据权利要求1-4所述的杂环化合物、其立体异构体或其药学上可接受的盐,其中,R1为氢或1至4个各自独立地选自卤素、羟基、巯基、氧代(=O)、硫代(=S)、C1~C4烷氧基、卤代C1~C4烷氧基、C1~C4烷硫基、C1~C4烷基、卤代C1~C4烷基、硝基、氨基、被C1~C4烷基取代的氨基、氰基、羧基、醛基、氨基C1~C4烷基、羟基C1~C4烷基、氰基C1~C4烷基、C1~C4烷酰基、卤代C1~C4烷酰基、磺酸基(-SO2OH)、磺酰氨基(-SO2NH2)、氨基甲酰基(-CONH2)、被C1~C4烷基取代的氨基甲酰基、羧基C1~C4烷基、C1~C4烷磺酰基、卤代C1~C4烷磺酰基、被C1~C4烷基取代的氨基C1~C4烷基、氨基 甲酰基C1~C4烷基或被C1~C4烷基取代的氨基甲酰基C1~C4烷基;R2为不存在,或者为1至3个各自独立地选自卤素、羟基、巯基、C1~C4烷氧基、卤代C1~C4烷氧基、C1~C4烷硫基、C1~C4烷基、卤代C1~C4烷基、硝基、氨基、被C1~C4烷基取代的氨基、氰基、羧基、醛基、羟基C1~C4烷基、氰基C1~C4烷基、C1~C4烷酰基、卤代C1~C4烷酰基、磺酸基(-SO2OH)、磺酰氨基(-SO2NH2)、氨基甲酰基(-CONH2)、被C1~C4烷基取代的氨基甲酰基、羧基C1~C4烷基、C1~C4烷磺酰基、卤代C1~C4烷磺酰基、氨基C1~C4烷基、被C1~C4烷基取代的氨基C1~C4烷基、氨基甲酰基C1~C4烷基或被C1~C4烷基取代的氨基甲酰基C1~C4烷基;R3为氢或1至4个各自独立地选自羟基或C1~C4烷基的取代基;L不存在,或者为C1~C4亚烷基,且该亚烷基非必须地被一个或多个选自羟基、C1~C6烷氧基和氧代基团(O=)中的取代基所取代;G环与L的连接方式为通过G环上的碳原子与L相连;并且,G环非必须地被一个或多个相同或不同取代基取代;所述G环上的取代基为卤素、C1~C4烷基、卤代C1~C4烷基、C1~C4烷氧基、卤代C1~C4烷氧基、硝基、氰基、羟基、巯基、氨基、被C1~C4烷基取代的氨基、叠氮基、C1~C4烷酰基、卤代C1~C4烷酰基、C2~C4链烯基、C2~C4炔基、羧基C1~C4烷基、氰基C1~C4烷基、C2~C4链烯氧基、C2~C4炔氧基、氨基甲酰基(-CONH2)、被C1~C4烷基取代的氨基甲酰基、羧基、羟基C1~C4烷基、氧代(=O)、硫代(=S)、磺酰氨基(-SO2NH2)、C1~C4烷硫基、C1~C4烷磺酰基、卤代C1~C4烷磺酰基、磺酸基(-SO2OH)、醛基、氨基C1~C4烷基、被C1~C4烷基取代的氨基C1~C4烷基、氨基甲酰基C1~C4烷基、被C1~C4烷基取代的氨基甲酰基C1~C4烷基、C3-C7环烃基、C3-C7环烃基C1~C4烷基、C3-C7环烃基甲酰胺基、呋喃基、噻吩基、吡咯基、吡咯烷基、吡唑基、吡唑烷基、三唑基、三唑烷基、噻唑基、噻唑烷基、异噻唑基、异噻唑烷基、噁唑基、噁唑烷基、异噁唑基、异噁唑烷基、吡喃基、吡嗪基、哌嗪基、哒嗪基、吡啶基、哌啶基、嘧啶基、咪唑基、C3-C7环烃基C1~C4烷氧基、呋喃基C1~C4烷基、呋喃基C1~C4烷氧基、噻吩基C1~C4烷基、噻吩基C1~C4烷氧基、吡咯基C1~C4烷基、吡咯基C1~C4烷氧基、吡咯烷基C1~C4烷基、吡咯烷基C1~C4烷氧基、吡唑基C1~C4烷基、吡唑基C1~C4烷氧基、三唑基C1~C4烷基、三唑基C1~C4烷氧基、噻唑基C1~C4烷基、噻唑基C1~C4烷氧基、异噻唑基C1~C4烷基、异噻唑基C1~C4烷氧基、噁唑基C1~C4烷基、噁唑基C1~C4烷氧基、异噁唑基C1~C4烷基、异噁唑基C1~C4烷氧基、吡嗪基C1~C4烷基、吡嗪基C1~4烷氧基、哒嗪基C1~C4烷基、哒嗪基C1~C4烷氧基、吡啶基C1~C4烷基、吡啶基C1~C4烷氧基、嘧啶基C1~C4烷基、嘧啶基C1~C4烷氧基、苯基、苯氧基、苯磺酰基、 苯基C1~C4烷基、苯基C1~C4烷氧基、苯基C1~C4烷酰基或苯基C1~C4烷酰氧基;上述C3-C7环烃基、C3-C7环烃基C1~C4烷基、呋喃基、噻吩基、吡咯基、吡咯烷基、吡唑基、吡唑烷基、三唑基、三唑烷基、噻唑基、噻唑烷基、异噻唑基、异噻唑烷基、噁唑基、噁唑烷基、异噁唑基、异噁唑烷基、吡喃基、吡嗪基、哌嗪基、哒嗪基、吡啶基、哌啶基、嘧啶基、咪唑基、C3-C7环烃基C1~C4烷氧基、呋喃基C1~C4烷基、呋喃基C1~C4烷氧基、噻吩基C1~C4烷基、噻吩基C1~C4烷氧基、吡咯基C1~C4烷基、吡咯基C1~C4烷氧基、吡咯烷基C1~C4烷基、吡咯烷基C1~C4烷氧基、吡唑基C1~C4烷基、吡唑基C1~C4烷氧基、三唑基C1~C4烷基、三唑基C1~C4烷氧基、噻唑基C1~C4烷基、噻唑基C1~C4烷氧基、异噻唑基C1~C4烷基、异噻唑基C1~C4烷氧基、噁唑基C1~C4烷基、噁唑基C1~C4烷氧基、异噁唑基C1~C4烷基、异噁唑基C1~C4烷氧基、吡嗪基C1~C4烷基、吡嗪基C1~4烷氧基、哒嗪基C1~C4烷基、哒嗪基C1~C4烷氧基、吡啶基C1~C4烷基、吡啶基C1~C4烷氧基、嘧啶基C1~C4烷基、嘧啶基C1~C4烷氧基、苯基、苯氧基、苯磺酰基、苯基C1~C4烷基、苯基C1~C4烷氧基、苯基C1~C4烷酰基和苯基C1~C4烷酰氧基非必须地被一个或多个选自如下基团的取代基所取代:卤素、C1~C4烷基、卤代C1~C4烷基、C1~C4烷氧基、C1~C4烷氧酰基、卤代C1~C4烷氧基、硝基、氰基、羟基、氨基、C1~C4烷酰基、卤代C1~C4烷酰基、氨基甲酰基或羧基。
- 根据权利要求5所述的杂环化合物、其立体异构体或其药学上可接受的盐,其中,R1为氢或1至4个各自独立地选自氟、氯、溴、羟基、巯基、氧代(=O)、硫代(=S)、甲氧基、乙氧基、三氟甲氧基、-SCH3、-SCH2CH3、甲基、乙基、丙基、异丙基、叔丁基、三氟甲基、溴甲基、氯甲基、硝基、氨基、N-甲基氨基、N-乙基氨基、N,N-二甲基氨基、N,N-二乙基氨基、氰基、羧基、醛基、-CH2NH2、-CH2CH2NH2、-CH2OH、-CH2CH2OH、-CH2CN、-CH2CH2CN、甲酰基、乙酰基、丙酰基、三氟乙酰基、磺酸基(-SO2OH)、磺酰氨基(-SO2NH2)、氨基甲酰基、N-甲基氨基甲酰基、N,N-二甲基氨基甲酰基、N-乙基氨基甲酰基、N,N-二乙基氨基甲酰基、-CH2CO2H、-CH2CH2CO2H、-SO2CH3、-SO2CF3、-CH2NHMe、-CH2NMe2、-CH2CONH2、-CH2CONHMe或-CH2CONMe2;R2不存在,或者为1至3个各自独立地选自氟、氯、溴、羟基、巯基、甲氧基、乙氧基、三氟甲氧基、-SCH3、-SCH2CH3、甲基、乙基、丙基、异丙基、叔丁基、三氟甲基、溴甲基、氯甲基、硝基、氨基、N-甲基氨基、N-乙基氨基、N,N-二甲基氨基、N,N-二乙基氨基、氰基、羧基、醛基、-CH2OH、-CH2CH2OH、-CH2CN、-CH2CH2CN、甲酰基、乙酰基、丙酰基、三氟乙酰基、磺酸基(-SO2OH)、磺酰氨基(-SO2NH2)、氨基甲酰基、N-甲基氨基甲酰基、N,N-二甲基氨基甲酰基、N-乙基氨基甲酰基、N,N-二乙基氨基甲酰 基、-CH2CO2H、-CH2CH2CO2H、-SO2CH3、-SO2CF3、-CH2NH2、-CH2CH2NH2、-CH2NHMe、-CH2NMe2、-CH2CONH2、-CH2CONHMe或-CH2CONMe2;R3为氢或1至4个各自独立地选自羟基、甲基或乙基的取代基;所述G环上的取代基为氟、氯、溴、甲基、乙基、丙基、异丙基、叔丁基、三氟甲基、甲氧基、乙氧基、三氟甲氧基、硝基、氰基、羟基、巯基、氨基、N-甲基氨基、N-乙基氨基、N,N-二甲基氨基、N,N-二乙基氨基、叠氮基、甲酰基、乙酰基、丙酰基、三氟乙酰基、-CH2CO2H、-CH2CH2CO2H、-CH2CN、-CH2CH2CN、氨基甲酰基、N-甲基氨基甲酰基、N,N-二甲基氨基甲酰基、N-乙基氨基甲酰基、N,N-二乙基氨基甲酰基、羧基、-CH2OH、-CH2CH2OH、氧代(=O)、硫代(=S)、磺酰氨基(-SO2NH2)、-SCH3、-SCH2CH3、-SO2CH3、-SO2CF3、磺酸基(-SO2OH)、醛基、-CH2NH2、-CH2CH2NH2、-CH2NHMe、-CH2NMe2、-CH2NHEt、-CH2NEt2、-CH2CH2NHMe、-CH2CH2NHEt、-CH2CH2NMe2、-CH2CH2NEt2、-CH2CONH2、-CH2CONHMe、-CH2CONMe2、-CH2CONHEt、-CH2CONEt2、-CH2CH2CONH2、-CH2CH2CONHMe、-CH2CH2CONMe2、-CH2CH2CONHEt、-CH2CH2CONEt2、苯基、苯氧基、苯磺酰基、-CH2Ph、-CH2CH2Ph、-OCH2Ph、-OCH2CH2Ph、-COPh、-COCH2Ph或-CH2Ph(OMe)2。
- 权利要求1-8中任一项所述的杂环化合物、其立体异构体或其药学上可接受的盐,其选自如下化合物:(1)6-氯-5-(2-(4-(2,3-二氢苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-2-酮;(2)3-(2-(4-(2,3-二氢苯并噻吩-4-基)哌嗪-1-基)乙基)-9-羟基-2-甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(3)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-2-甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(4)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-9-羟基-2-甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(4a)(+)-3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-9-羟基-2-甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(4b)(-)-3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-9-羟基-2-甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(5)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-2-甲基-7,8-二氢-6H-吡啶并[1,2-a]嘧啶-4,9-二酮;(6)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-9-羟基-2,9-二甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(7)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-9-氟-2-甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(8)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-2-酮;(9)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)喹啉-2(1H)-酮;(10)7-(5-(4-(苯并噻吩-4-基)哌嗪-1-基)戊基)-3,4-二氢喹啉-2(1H)-酮;(11)7-(5-(4-(苯并噻吩-4-基)哌嗪-1-基)戊基)喹啉-2(1H)-酮;(12)7-(5-(4-(2-氯苯并噻吩-4-基)哌嗪-1-基)戊基)喹啉-2(1H)-酮;(13)7-(5-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)戊基)喹啉-2(1H)-酮;(14)7-(5-(4-(苯并噻吩-4-基)-5,6-二氢吡啶-1(2H)-基)戊基)喹啉-2(1H)-酮;(15)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-6-氯二氢吲哚-2-酮;(16)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-2-甲基-6,7-二氢吡啶并[1,2-a]嘧啶-4-酮;(17)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-9-(苄氧基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮;(18)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮;(19)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(20)9-羟基-2-甲基-3-(2-(4-(噻吩并[2,3-d]嘧啶-4-基)哌嗪-1-基)乙基)-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(21)2-甲基-3-(2-(4-(噻吩并[2,3-d]嘧啶-4-基)哌嗪-1-基)乙基)-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(22)7-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)-3,4-二氢喹啉-2(1H)-酮;(23)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-6-氯-3,4-二氢喹啉-2(1H)-酮;(24)6-(5-(4-(苯并噻吩-4-基)哌嗪-1-基)戊基)-2-甲基喹唑啉-4(3H)-酮;(25)7-(2-(4-(2,3-二氢苯并噻吩-4-基)哌嗪-1-基)乙基)喹啉-2(1H)-酮;(26)1-(苯并噻吩-4-基)-4-(2-(4-甲基噻唑-5-基)乙基)哌嗪;(27)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1,3-二氢苯并咪唑-2-酮;(28)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-9,9-二氟-2-甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(29)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基-2(3H)-苯并噻唑酮;(30)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基-2H-1,4-苯并噁嗪-3(4H)-酮;(31)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基-2H-1,4-苯并噻嗪-3(4H)-酮;(32)7-(2-(4-(噻吩并[2,3-d]嘧啶-4-基)哌嗪-1-基)乙基)喹啉-2(1H)-酮;(33)7-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)喹啉-2(1H)-酮;(34)6-(5-(4-(苯并噻吩-4-基)哌嗪-1-基)戊基)喹唑啉-4(3H)-酮;(35)2-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)喹唑啉-4(3H)-酮;(36)3-(2-(4-(苯并噻吩-4-基)哌啶-1-基)乙基)-9-羟基-2-甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(37)5-(2-(4-(苯并噻吩-4-基)哌啶-1-基)乙基)-6-氯-二氢吲哚-2-酮;(38)4-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-2-酮;(39)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-2-酮;(40)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-6-氯喹啉-2(1H)-酮;(41)9-羟基-2-甲基-3-(2-(4-(噻吩并[2,3-c]吡啶-4-基)哌嗪-1-基)乙基)-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(42)6-氯-5-(2-(4-(噻吩并[2,3-c]吡啶-4-基)哌嗪-1-基)乙基)二氢吲哚-2-酮;(43)7-(2-(4-(噻吩并[2,3-c]吡啶-4-基)哌嗪-1-基)乙基)喹啉-2(1H)-酮;(44)7-(3-(4-(苯并噻吩-4-基)哌嗪-1-基)丙基)喹啉-2(1H)-酮;(45)7-(3-(4-(苯并噻吩-4-基)哌嗪-1-基)丙基-3,4-二氢喹啉-2(1H)-酮;(46)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1H-吲哚;(47)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(48)5-(3-(4-(苯并噻吩-4-基)哌嗪-1-基)丙基)二氢吲哚-2-酮;(49)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-4,5-二氢-1H-苯并氮杂卓-2(3H)-酮;(50)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮;(51)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-3-甲基-3,4-二氢喹唑啉-2(1H)-酮;(52)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-9-氯-2-甲基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮;(53)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-2-硫酮;(54)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)喹啉-2(1H)-硫酮;(55)2-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-5,6-二乙基嘧啶-4(3H)-酮;(56)2-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)嘧啶-4(3H)-酮;(57)7-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)喹啉-2(1H)-酮;(58)2-((4-(苯并噻吩-4-基)哌嗪-1-基)甲基)-1H-苯并咪唑;(59)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑;(60)7-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-胺;(61)N-(7-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-基)乙酰胺;(62)5-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-胺;(63)N-(5-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-基)乙酰胺;(64)7-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(65)6-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(66)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-7-氟-2H-苯并[1,4]噁嗪-3(4H)-酮;(67)7-(2-(4-(3-甲基苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(68)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噁唑-2(3H)-酮;(69)4-((4-(苯并噻吩-4-基)哌嗪-1-基)甲基)喹啉-2(1H)-酮;(70)3-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)-1H-吲哚-5-甲腈;(71)7-(5-(4-(6-氟苯并噻吩-4-基)哌嗪-1-基)戊基)喹啉-2(1H)-酮;(72)6-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)-8-氟-2H-苯并[1,4]噁嗪-3(4H)-酮;(73)1-(苯并噻吩-4-基)-4-((2,3-二氢苯并[1,4]二氧杂环己烯-2-基)甲基)哌嗪;(74)6-(4-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)丁基)-3,4-二氢喹啉-2(1H)-酮;(75)2-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1H-苯并咪唑;(76)N-(6-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-基)乙酰胺;(77)5-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)-1H-苯并咪唑-2(3H)-酮;(78)6-(2-(4-(6-氟苯并噻吩-4-基)哌嗪-1-基)乙基)-2H-苯并[1,4]噁嗪-3(4H)-酮;(79)5-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-2-酮;(80)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-2-甲基喹唑啉-4(3H)-酮;(81)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1,1-二氧代-3,4-二氢-2H-苯并[1,2]噻嗪;(82)5-(2-(4-(苯并噻吩-4-基)哌啶-1-基)乙基)二氢吲哚-2-酮;(83)7-(2-(4-(苯并噻吩-4-基)哌啶-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(84)5-(2-(4-(6-氟苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-2-酮;(85)7-(2-(4-(6-氟苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(86)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1-甲基-1H-苯并咪唑-2(3H)-酮;(87)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1,3-二甲基-1H-苯并咪唑-2(3H)-酮;(88)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1-甲基-1H-苯并咪唑-2(3H)-酮;(89)6-(2-(4-(2-甲氧基苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(90)3-(2-(4-(6-氟苯并噻吩-4-基)哌嗪-1-基)乙基)-2-甲基-6,7,8,9-四氢-4H-吡啶并[1,2-a]嘧啶-4-酮;(91)7-(2-(4-(2-氧代-2,3-二氢苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(92)6-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)-2H-苯并[1,4]噁嗪-3(4H)-酮;(93)5-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)-1,3-二甲基-1H-苯并咪唑-2(3H)-酮;(94)6-氟-5-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-2-酮;(95)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-6-氟二氢吲哚-2-酮;(96)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1-苄基-3-甲基喹唑啉-2,4(1H,3H)-二酮;(97)6-(2-(4-(苯并噻吩-4-基)哌啶-1-基)乙基)-2H-苯并[1,4]噁嗪-3(4H)-酮;(98)6-(2-(4-(苯并噻吩-4-基)哌啶-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(99)3-(2-(4-(苯并噻吩-4-基)哌啶-1-基)乙基)-2-甲基-6,7,8,9-四氢-4H-吡啶并[1,2-a]嘧啶-4-酮;(100)6-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)喹啉-2(1H)-酮;(101)5-(4-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)丁基)二氢吲哚-2-酮;(102)7-(2-(4-(6-氟苯并噻吩-4-基)哌嗪-1-基)乙基)喹啉-2(1H)-酮;(103)3-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)-6,7-二甲氧基-4H-色烯-4-酮;(104)6-(4-(4-(苯并噻吩-4-基)哌啶-1-基)丁基)-3,4-二氢喹啉-2(1H)-酮;(105)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-5-甲氧基-1H-吲哚;(106)3-(3-(4-(苯并噻吩-4-基)哌嗪-1-基)丙基)-5-甲氧基-1H-吲哚;(107)3-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)-5-甲氧基-1H-吲哚;(108)3-(3-(4-(苯并噻吩-4-基)哌嗪-1-基)丙基)-1H-吲哚-5-甲腈;(109)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1H-吲哚-5-甲腈;(110)1-乙酰基-3-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)-1H-吲哚-5-甲腈;(111)6-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)-3,4-二氢喹啉-2(1H)-酮;(112)5-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)二氢吲哚-2-酮;(113)6-氯-5-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-2-酮;(114)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-4-甲基-2H-苯并[1,4]噁嗪-3(4H)-酮;(115)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1-甲基-3,4-二氢喹啉-2(1H)-酮;(116)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-胺;(117)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-胺;(118)N-(5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-基)乙酰胺;(119)N-(7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-基)乙酰胺;(120)4-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-胺;(121)N-(4-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-基)乙酰胺;(122)7-(2-(4-(2-甲基苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(123)3-((4-(苯并噻吩-4-基)哌嗪-1-基)甲基)-1-甲基-1H-吲哚;(124)1-(3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)二氢吲哚-1-基)乙酮;(125)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-1-对甲苯磺酰基-1H-吲哚-5-甲腈;(126)3-(3-(4-(苯并噻吩-4-基)哌嗪-1-基)丙基)-1-对甲苯磺酰基-1H-吲哚-5-甲腈;(127)3-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)-5-甲氧基-1-对甲苯磺酰基-1H-吲哚;(128)3-(3-(4-(苯并噻吩-4-基)哌嗪-1-基)丙基)-5-甲氧基-1-对甲苯磺酰基-1H-吲哚;(129)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-5-甲氧基-1-对甲苯磺酰基-1H-吲哚;(130)6-(2-(4-(2-氧代-2,3-二氢苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-酮;(131)3-(2-(4-(2-氟苯并噻吩-4-基)哌嗪-1-基)乙基)-9-羟基-2-甲基-6,7,8,9-四氢-4H-吡啶并[1,2-a]嘧啶-4-酮;(132)2-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-2H-苯并[1,4]噁嗪-3(4H)-酮;(133)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-3,4-二氢喹啉-2(1H)-硫酮;(134)(3aR,4R,6aS)-4-(5-(4-(苯并噻吩-4-基)哌嗪-1-基)戊基)四氢-1H-噻吩并[3,4-d]咪唑-2(3H)-酮;(135)(6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-基)氨基甲酸戊酯;(136)3-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-2-甲基-4-氧代-6,7,8,9-四氢-4H-吡啶并[1,2-a]嘧啶-9-基苯甲酸酯;(137)6-(4-(4-(苯并噻吩-4-基)哌嗪-1-基)丁基)-2H-苯并[1,4]噁嗪-3(4H)-酮;(138)1-(苯并噻吩-4-基)-4-(4-(1-环己基-1H-四唑-5-基)丁基)哌嗪;(139)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)-8-氟-2H-苯并[1,4]噁嗪-3(4H)-酮;(140)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)-1-羟乙基)喹啉-2(1H)-酮;(141)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)-1-羟基乙基)-2H-苯并[1,4]噁嗪-3(4H)-酮;(142)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)-1-羟基乙基)-2H-苯并[1,4]噻嗪-3(4H)-酮;(143)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙酰基)二氢吲哚-2-酮;(144)8-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)-1-甲氧基乙基)-2H-苯并[1,4]噁嗪-3(4H)-酮;(145)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)-1-羟基乙基)二氢吲哚-2-酮;(146)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙酰基)苯并噻唑-2(3H)-酮;(147)5-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙酰基)-1H-苯并咪唑-2(3H)-酮;(148)7-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙酰基)-3,4-二氢喹啉-2(1H)-酮;(149)7-(5-(4-(苯并噻吩-4-基)哌嗪-1-基)戊酰基)喹啉-2(1H)-酮;(150)7-(5-(4-(苯并噻吩-4-基)哌嗪-1-基)-1-羟基戊基)-3,4-二氢喹啉-2(1H)-酮;(151)7-(5-(4-(苯并噻吩-4-基)哌嗪-1-基)戊酰基)-3,4-二氢喹啉-2(1H)-酮;(152)N-(6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-基)环戊甲酰胺;(153)N-(6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-基)乙酰胺;(154)6-(2-(4-(苯并噻吩-4-基)哌嗪-1-基)乙基)苯并噻唑-2-胺。
- 一种药物组合物,其包含治疗有效量的选自权利要求1~9中任一项所述的杂环化合物、其立体异构体或其药学上可接受的盐和任选的可药用载体。
- 一种制备药物组合物的方法,包括将权利要求1~9中任一项所述的杂环化合物、其立体异构体或其药学上可接受的盐与可药用载体混合。
- 权利要求1~9中任一项所述的杂环化合物、其立体异构体或其药学上可接受的盐在制备预防和/或治疗中枢神经系统疾病的药物中的应用。
- 权利要求12所述的应用,其中所述枢神经系统疾病选自:精神分裂症;难控制的、难处理的或慢性精神分裂症;情感紊乱;精神紊乱;情绪紊乱;I型双极情感障碍;II型双极情感障碍;抑郁症;内因性抑郁症;重性抑郁症;难控制的抑郁症;情绪恶劣性障碍;循环情感性障碍;恐慌发作;惊恐性障碍;社交恐惧症;强迫性观念与行为病症;冲动性病症;创伤后精神紧张性障碍;焦虑症;急性应激障碍;癔病;神经性厌食症;睡眠障碍;适应性障碍;认知障碍;自闭症;神经性头痛;狂躁症;帕金森症;亨廷顿舞蹈症;阿尔茨海默症;各种痴呆症;记忆障碍;多动症;注意力缺乏/亢进类疾病和抽动症。
- 制备权利要求1~9中任一项所述的的杂环化合物、其立体异构体或其药学上可接受的盐的方法,其可按如下方法1~5中的一种进行:方法1:由式(II)所示化合物或其盐与式(III)所示化合物或其盐进行反应,如反应式1所示:其中,G环、L、A、B、D、E、R1、R2和R3的定义同相应权利要求中的定义相同;X代表离去基团,如卤素、C1~C6烷基磺酰氧基、苯磺酰氧基、萘磺酰氧基,上述C1~C6烷基磺酰氧基、苯磺酰氧基、萘磺酰氧基可非必须地被一个或多个选自卤素、C1~C6烷基、C1~C6烷氧基、硝基、羟基、氨基和C1~C6烷酰基的基团进一步取代;方法2:式(IV)所示的化合物或其盐与式(V)所示的化合物或其盐进行反应,如反应式2所示:其中,G环、L、A、B、D、R1、R2和R3的定义与相应权利要求中的定义相同,E1代表氮原子;X1代表卤素或三氟甲磺酰氧基;方法3:式(VI)所示化合物或其盐与式(III)所示化合物或其盐经酰胺化反应得到式(VII)化合物或其盐;式(VII)化合物或其盐用还原剂处理,得到式(I)化合物,如反应式3所示:其中,G环、L、A、B、D、E、R1、R2和R3的定义与相应权利要求中的定义相同;方法4:式(VIII)所示化合物或其盐与式(III)所示化合物或其盐经还原胺化反应得到式(I)化合物,如反应式4所示:其中,G环、L、A、B、D、E、R1、R2和R3的定义与相应权利要求中的定义相同;方法5:由方法1~4得到的式(I)化合物进行官能团转化得到。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016556278A JP6395850B2 (ja) | 2014-03-07 | 2015-03-09 | 複素環式化合物、その製造方法および使用 |
CA2941771A CA2941771C (en) | 2014-03-07 | 2015-03-09 | Heterocyclic compounds, process for preparation of the same and use thereof |
RU2016137169A RU2667498C2 (ru) | 2014-03-07 | 2015-03-09 | Гетероциклические соединения, способ их получения и их применение |
CN201580008897.5A CN106132956B (zh) | 2014-03-07 | 2015-03-09 | 一类杂环化合物、其制备方法和用途 |
AU2015226578A AU2015226578B2 (en) | 2014-03-07 | 2015-03-09 | Heterocyclic compounds, process for preparation of the same and use thereof |
EP15757771.9A EP3115361B1 (en) | 2014-03-07 | 2015-03-09 | Heterocyclic compounds, and preparation method and use thereof |
KR1020167027945A KR101840249B1 (ko) | 2014-03-07 | 2015-03-09 | 헤테로고리 화합물 및 이의 제조방법과 용도 |
US15/124,264 US10174011B2 (en) | 2014-03-07 | 2015-03-09 | Heterocyclic compounds, process for preparation of the same and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410083602 | 2014-03-07 | ||
CN201410083602.8 | 2014-03-07 | ||
CN201410853950.9A CN104892589A (zh) | 2014-03-07 | 2014-12-31 | 一类杂环化合物、其制备方法和用途 |
CN201410853950.9 | 2014-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015131856A1 true WO2015131856A1 (zh) | 2015-09-11 |
Family
ID=54025602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/073854 WO2015131856A1 (zh) | 2014-03-07 | 2015-03-09 | 一类杂环化合物、其制备方法和用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10174011B2 (zh) |
EP (1) | EP3115361B1 (zh) |
JP (1) | JP6395850B2 (zh) |
KR (1) | KR101840249B1 (zh) |
CN (2) | CN104892589A (zh) |
AU (1) | AU2015226578B2 (zh) |
CA (1) | CA2941771C (zh) |
RU (1) | RU2667498C2 (zh) |
WO (1) | WO2015131856A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3244898A4 (en) * | 2015-01-12 | 2018-08-22 | Reviva Pharmaceuticals, Inc. | Methods for treating psychosis associated with parkinson's disease |
EP3244897A4 (en) * | 2015-01-12 | 2018-08-22 | Reviva Pharmaceuticals, Inc. | Methods for treating alzheimer's disease |
EP3244896A4 (en) * | 2015-01-12 | 2018-08-29 | Reviva Pharmaceuticals, Inc. | Methods for treating pulmonary hypertension |
JP2018529727A (ja) * | 2015-10-02 | 2018-10-11 | クリスタル ファルマ、エセ、ア、ウCrystal Pharma,S.A.U. | ベンゾ[b]チオフェン化合物を製造するための方法および中間体 |
US10100044B2 (en) * | 2013-10-18 | 2018-10-16 | Suzhou Vigonvita Life Sciences Co., Ltd. | Methods for preparing brexpiprazole, key intermediates thereof and salts thereof |
WO2019242717A1 (zh) | 2018-06-21 | 2019-12-26 | 中国科学院上海药物研究所 | 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途 |
WO2023186023A1 (zh) * | 2022-03-30 | 2023-10-05 | 苏州旺山旺水生物医药股份有限公司 | 一类n-取代的喹啉酮化合物、其制备方法和用途 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105461608B (zh) * | 2015-11-23 | 2017-11-28 | 东南大学 | 二氢吲哚‑2‑酮类d3受体配体及其制备方法和用途 |
US10464931B2 (en) | 2015-12-28 | 2019-11-05 | Honour (R&D) | Process for the preparation of Quinolin-2(1H)-one derivatives |
CN106478548A (zh) * | 2016-07-19 | 2017-03-08 | 贵州大学 | 一种6‑羟基灭草松的制备工艺 |
CN107098855A (zh) * | 2017-04-05 | 2017-08-29 | 上海诺星医药科技有限公司 | 一种制备7‑羟基‑2‑喹啉酮的方法 |
CN111004211B (zh) * | 2019-12-29 | 2021-04-02 | 苏州诚和医药化学有限公司 | 一种依匹哌唑中间体4-溴苯并[b]噻吩的合成方法 |
US11851435B2 (en) * | 2022-03-07 | 2023-12-26 | National Health Research Institutes | PTGR2 inhibitors and their use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101754964A (zh) * | 2007-07-19 | 2010-06-23 | 库多斯药物有限公司 | Dna pk抑制剂 |
WO2013024291A2 (en) * | 2011-08-18 | 2013-02-21 | Ucb Pharma S.A. | Therapeutically active fused pyrimidine derivatives |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4771053A (en) | 1987-03-02 | 1988-09-13 | Bristol-Myers Company | Method for alleviation of primary depressive disorders |
US5824680A (en) | 1991-08-31 | 1998-10-20 | Bayer Aktiengesellschaft | Ipsapirone for the treatment of alzheimer's disease by improving memory |
US5137894A (en) * | 1991-12-05 | 1992-08-11 | New James S | 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides |
HN1999000146A (es) | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. |
GB2370270A (en) * | 2000-12-20 | 2002-06-26 | Lilly Co Eli | Pharmaceutical compounds |
GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
UA84566C2 (ru) * | 2004-06-09 | 2008-11-10 | Солвей Фармасьютикалс Б.В. | Производные тиофенпиримидинонов и их применение в терапии, фармацевтическая композиция на их основе |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP2008037850A (ja) * | 2006-08-10 | 2008-02-21 | Mitsubishi Tanabe Pharma Corp | 新規置換ピペリジン誘導体 |
WO2008047883A1 (en) * | 2006-10-13 | 2008-04-24 | Otsuka Pharmaceutical Co., Ltd. | Piperazine-substituted benzothiophenes for treatment of mental disorders |
JP2008115175A (ja) * | 2006-10-13 | 2008-05-22 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
JP4540700B2 (ja) | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
AU2009206580A1 (en) * | 2008-01-25 | 2009-07-30 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
WO2010030757A2 (en) | 2008-09-10 | 2010-03-18 | Kalypsys Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
CA2987743A1 (en) * | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Purine derivatives and their use as immunosuppressive agents |
CA2773131C (en) * | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
KR101756495B1 (ko) * | 2010-03-11 | 2017-07-10 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | N-아실 시클릭 아민 유도체 또는 이의 의약상 허용되는 염 |
GB201012889D0 (en) * | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
JP2014162781A (ja) * | 2013-02-27 | 2014-09-08 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
WO2016003296A1 (en) * | 2014-07-04 | 2016-01-07 | Instytut Farmakologii Polskiej Akademii Nauk | (quinoline or isoquinoline)sulfonamides of cyclic amines as antipsychotic drugs |
-
2014
- 2014-12-31 CN CN201410853950.9A patent/CN104892589A/zh active Pending
-
2015
- 2015-03-09 EP EP15757771.9A patent/EP3115361B1/en active Active
- 2015-03-09 CN CN201580008897.5A patent/CN106132956B/zh active Active
- 2015-03-09 RU RU2016137169A patent/RU2667498C2/ru active
- 2015-03-09 WO PCT/CN2015/073854 patent/WO2015131856A1/zh active Application Filing
- 2015-03-09 AU AU2015226578A patent/AU2015226578B2/en not_active Ceased
- 2015-03-09 KR KR1020167027945A patent/KR101840249B1/ko active IP Right Grant
- 2015-03-09 CA CA2941771A patent/CA2941771C/en active Active
- 2015-03-09 US US15/124,264 patent/US10174011B2/en active Active
- 2015-03-09 JP JP2016556278A patent/JP6395850B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101754964A (zh) * | 2007-07-19 | 2010-06-23 | 库多斯药物有限公司 | Dna pk抑制剂 |
WO2013024291A2 (en) * | 2011-08-18 | 2013-02-21 | Ucb Pharma S.A. | Therapeutically active fused pyrimidine derivatives |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10100044B2 (en) * | 2013-10-18 | 2018-10-16 | Suzhou Vigonvita Life Sciences Co., Ltd. | Methods for preparing brexpiprazole, key intermediates thereof and salts thereof |
EP3244898A4 (en) * | 2015-01-12 | 2018-08-22 | Reviva Pharmaceuticals, Inc. | Methods for treating psychosis associated with parkinson's disease |
EP3244897A4 (en) * | 2015-01-12 | 2018-08-22 | Reviva Pharmaceuticals, Inc. | Methods for treating alzheimer's disease |
EP3244896A4 (en) * | 2015-01-12 | 2018-08-29 | Reviva Pharmaceuticals, Inc. | Methods for treating pulmonary hypertension |
US10441590B2 (en) | 2015-01-12 | 2019-10-15 | Reviva Pharmaceuticals, Inc. | Methods for treating pulmonary hypertension |
JP2018529727A (ja) * | 2015-10-02 | 2018-10-11 | クリスタル ファルマ、エセ、ア、ウCrystal Pharma,S.A.U. | ベンゾ[b]チオフェン化合物を製造するための方法および中間体 |
WO2019242717A1 (zh) | 2018-06-21 | 2019-12-26 | 中国科学院上海药物研究所 | 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途 |
US11384073B2 (en) * | 2018-06-21 | 2022-07-12 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Maleate salt of benzothiophene compound, crystalline form thereof, and use thereof |
WO2023186023A1 (zh) * | 2022-03-30 | 2023-10-05 | 苏州旺山旺水生物医药股份有限公司 | 一类n-取代的喹啉酮化合物、其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN104892589A (zh) | 2015-09-09 |
RU2667498C2 (ru) | 2018-09-21 |
CA2941771A1 (en) | 2015-09-11 |
RU2016137169A (ru) | 2018-03-21 |
RU2016137169A3 (zh) | 2018-03-21 |
KR101840249B1 (ko) | 2018-03-20 |
EP3115361B1 (en) | 2019-10-23 |
AU2015226578B2 (en) | 2017-11-23 |
KR20160122269A (ko) | 2016-10-21 |
AU2015226578A1 (en) | 2016-10-20 |
CN106132956B (zh) | 2019-12-10 |
CN106132956A (zh) | 2016-11-16 |
JP2017508756A (ja) | 2017-03-30 |
JP6395850B2 (ja) | 2018-09-26 |
CA2941771C (en) | 2020-02-18 |
EP3115361A1 (en) | 2017-01-11 |
US10174011B2 (en) | 2019-01-08 |
EP3115361A4 (en) | 2017-04-26 |
US20170158680A1 (en) | 2017-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106132956B (zh) | 一类杂环化合物、其制备方法和用途 | |
US10556908B2 (en) | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | |
CN104470902B (zh) | N‑(3‑杂芳基芳基)‑4‑芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 | |
CN101048414B (zh) | 用于治疗精神障碍的稠合的三环衍生物 | |
CN105315285B (zh) | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 | |
WO2021088945A1 (zh) | 作为shp2抑制剂的化合物及其应用 | |
TWI413522B (zh) | 苯并二氮呯化合物及藥學組成物 | |
US20120178742A1 (en) | Metabotropic glutamate receptor modulators | |
WO2016007731A1 (en) | Imidazopyridines and imidazopyrazines as lsd1 inhibitors | |
WO2002032872A1 (en) | Nitrogenous aromatic ring compounds | |
TW200843777A (en) | Inhibitors of the hedgehog pathway | |
AU2013339167A1 (en) | Novel amine derivative or salt thereof | |
WO2016169504A1 (zh) | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 | |
WO2017114512A1 (zh) | 含氮稠杂环化合物、制备方法、中间体、组合物和应用 | |
EP3426244B1 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
JPWO2019208812A1 (ja) | ベンゾイソオキサゾール化合物 | |
WO2019034031A1 (zh) | 一类四氢原小檗碱类化合物,其制备方法、用途及药物组合物 | |
WO2017101796A1 (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
WO2018019252A1 (en) | Novel fused pyridine derivatives useful as fak/aurora kinase inhibitors | |
CN103087050A (zh) | 芳基激酶抑制剂 | |
CN107690434B (zh) | 作为tnf活性调节剂的稠合三环咪唑并吡嗪衍生物 | |
WO2019076336A1 (zh) | 含吡唑基的三并环类衍生物、其制备方法和应用 | |
WO2018228275A1 (zh) | 作为mnk抑制剂的杂环化合物 | |
CA2937012A1 (en) | Fused pyrazole derivative | |
TW201607941A (zh) | T型鈣通道阻礙劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15757771 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016556278 Country of ref document: JP Kind code of ref document: A Ref document number: 2941771 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15124264 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016137169 Country of ref document: RU Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015757771 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015757771 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20167027945 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015226578 Country of ref document: AU Date of ref document: 20150309 Kind code of ref document: A |